TomoTherapy for post-mastectomy radiotherapy (PMRT):  comparison with conventional electron beam technique by Ashenafi, Michael Sissay
Louisiana State University
LSU Digital Commons
LSU Master's Theses Graduate School
2006
TomoTherapy for post-mastectomy radiotherapy
(PMRT): comparison with conventional electron
beam technique
Michael Sissay Ashenafi
Louisiana State University and Agricultural and Mechanical College, michaeleth@gmail.com
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_theses
Part of the Physical Sciences and Mathematics Commons
This Thesis is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU
Master's Theses by an authorized graduate school editor of LSU Digital Commons. For more information, please contact gradetd@lsu.edu.
Recommended Citation
Ashenafi, Michael Sissay, "TomoTherapy for post-mastectomy radiotherapy (PMRT): comparison with conventional electron beam
technique" (2006). LSU Master's Theses. 4183.
https://digitalcommons.lsu.edu/gradschool_theses/4183
TOMOTHERAPY FOR POST-MASTECTOMY RADIOTHERAPY 















Submitted to the Graduate Faculty of the  
Louisiana State University and  
Agricultural and Mechanical College  
in partial fulfillment of the  
requirements for the degree of  






















Michael Sissay Ashenafi 
















This work is dedicated to my late grandmother,  
Adada  





My gratitude goes to Almighty God for giving me strength and helping me to reach 
where I am right now. 
 I thank my major advisor, Dr. Robert Boyd, who was always encouraging and 
motivating, and had endless patience with me. Without his help, I would have been 
overwhelmed. I also would like to thank Dr. Kenneth Hogstrom. He was a great teacher 
and mentor; I learned volumes from him. Also I would like to thank my other committee 
members: Drs. Greg Stacy, Kenneth Lo, and John Gibbons. They provided invaluable 
assistance in developing the project. I also wish to express my appreciation to Dr. Tae 
Kyu Lee for developing an “in house” radiation biological program. 
 A special thanks is extended to Mary Bird Perkins Cancer Center for allowing me to 
use their facility for my thesis research project. I would also like to thank all the staff at 
MBPCC; they are a wealth of knowledge that is impossible to fully appreciate.  
I wish to thank Drs. Henry Hardy, Mostafa Elaasar, Diola Bagayoko, Kenneth 
Mathews, Dennis Cheek, Oscar Hidalgo, Erno Sajeo, Mr. Connel Chu and Ms. Yvonne 
Thomas for their constant support throughout my matriculation, without them I would not 
be where I am right now. 
I would like to convey special appreciation to my family: grand parents: A. Asfaw 
and T. Asfaw, my parents: S. Ashenafi and B. Abraham, my siblings: Nebiat, Mary, and 
Adoni, my aunt and uncle in-law: Emebet Abraham and Fikru. Thank you for your 
endless sacrifices and unconditional love. I feel blessed to have such a wonderful family.  
My acknowledgements would not be complete if I would not thank my friends. 
Selam, words are not enough to say how grateful I am to know you. 
 iv 
Table of Contents 
Acknowledgements....................................................................................................... iii 
List of Tables ............................................................................................................... vii 




1.2 Significance of TomoTherapy vs. Electron Beams ............................................3 
1.3 Postmastectomy Radiation Therapy (PMRT).....................................................5 
1.3.1 Overview....................................................................................................5 
1.3.2 Conventioanl Electron PMRT Technique..................................................6 
1.3.3 Complication Associated with PMRT .......................................................7 
1.3.4 IMRT..........................................................................................................9 
1.4 Hypothesis/Specific Aims.................................................................................10 
2. Materials and Methods............................................................................................12 
2.1 Overview of Study ............................................................................................12 
2.2 Aim 1: Patient Database....................................................................................13 
2.3 Aim 2: TomoTherapy PMRT Treatment Plans ................................................17 
2.3.1 Importing CT Data...................................................................................17 
2.3.2 TomoTherapy Dose Prescription .............................................................17 
2.3.3 TomoTherapy Plan Parameters................................................................18 
2.3.4 Dose Limiting Structures ........................................................................18 
2.3.5 TomoTherapy Optimization and Dose Calculation .................................19 
2.4 Aim 3: Generate Dose-Volume Treatment Plan Metrics..................................22 
2.5 Aim 4: Radiation Oncologist Evaluation of Treatment Plans ..........................23 
2.6 Aim 5: Determine Biological Treatment Plan Evaluation Tools .....................24 
 2.6.1 Tumor Control Probability (TCP)............................................................24 
2.6.2 Normal Tissue Complication Probability (NTCP) for The Lung ............26 
2.6.3 Normal Tissue Complication Probability (NTCP) for The Heart............27 
2.6.4 Secondary Cancer Complication Probability (SCCP) for The Lung .......28 
3. Results ....................................................................................................................32 
3.1 Format for Presenting Results of Each Patient .................................................32 
3.2 Patient One........................................................................................................33 
3.2.1 Isodose Comparisons ...............................................................................33 
3.2.2 DVH Comparisons...................................................................................37 
3.2.3 Radiation Oncologist Review ..................................................................38 
3.2.4 Chest Wall................................................................................................39 
3.2.5 Ipsilateral Lung ........................................................................................40 
3.2.6 Heart.........................................................................................................40 
3.2.7 Contralateral Breast .................................................................................41 
 v 
3.2.8 Normal Tissue..........................................................................................42 
3.3 Patient Two .......................................................................................................42 
3.3.1 Isodose Comparisons ...............................................................................42 
3.3.2 DVH Comparisons...................................................................................47 
3.3.3 Radiation Oncologist Review ..................................................................47 
3.3.4 Chest Wall................................................................................................48 
3.3.5 Ipsilateral Lung ........................................................................................48 
3.3.6 Heart.........................................................................................................49 
3.3.7 Contralateral Breast .................................................................................49 
3.3.8 Normal Tissue..........................................................................................49 
3.4 Patient Three .....................................................................................................50 
3.4.1 Isodose Comparisons ...............................................................................50 
3.4.2 DVH Comparisons...................................................................................55 
3.4.3 Radiation Oncologist Review ..................................................................56 
3.4.4 Chest Wall................................................................................................56 
3.4.5 Ipsilateral Lung ........................................................................................56 
3.4.6 Heart.........................................................................................................57 
3.4.7 Contralateral Breast .................................................................................57 
3.4.8 Normal Tissue..........................................................................................57 
3.5 Patient Four.......................................................................................................58 
3.5.1 Isodose Comparisons ...............................................................................58 
3.5.2 DVH Comparisons...................................................................................60 
3.5.3 Radiation Oncologist Review ..................................................................63 
3.5.4 Chest Wall................................................................................................63 
3.5.5 Ipsilateral Lung ........................................................................................64 
3.5.6 Heart.........................................................................................................64 
3.5.7 Contralateral Breast .................................................................................65 
3.5.8 Normal Tissue..........................................................................................65 
3.6 Patient Five .......................................................................................................65 
3.6.1 Isodose Comparisons ...............................................................................66 
3.6.2 DVH Comparisons...................................................................................70 
3.6.3 Radiation Oncologist Review ..................................................................70 
3.6.4 Chest Wall................................................................................................71 
3.6.5 Ipsilateral Lung ........................................................................................71 
3.6.6 Heart.........................................................................................................71 
3.6.7 Contralateral Breast .................................................................................72 
3.6.8 Normal Tissue..........................................................................................72 
3.7 Summary: Tables of Review  ...........................................................................72 
3.7.1 Chest Wall................................................................................................73 
3.7.2 Lung .........................................................................................................74 
3.7.3 Heart.........................................................................................................76 
3.7.4 Contralateral Breast .................................................................................78 




4. Discussions ..............................................................................................................81 
4.1 Similarities Between The TomoTherapy and Conventional Plans ...................81 
4.2 Differences Between the TomoTherapy and Conventional Plans ....................81 
4.3 Overview of Doctor’s Review ..........................................................................84 
5. Conclusions...............................................................................................................86 
6. Future Works ............................................................................................................87 
6.1 Additional Treatment Studies ...........................................................................87 
6.2 Accuracy of Dose Calculation on Surface ........................................................87 
 6.3 Impact of Breathing Motion..............................................................................87 
6.4 Utility of Skin Collimation ...............................................................................88 
References ....................................................................................................................89 
Appendix A: Radiation Oncologist Evaluation of Treatment Plans .............................93 
Appendix B: Acronyms ................................................................................................95 
Vita................................................................................................................................96 
 vii 
List of Tables 
1. TomoTherapy plan parameter specifications .........................................................18 
2. Table 2. Typical PTV (a) and RAR (b) constraints upon completion of      
optimization ............................................................................................................21 
3. Radiation oncologist specifications .......................................................................23 
4. Parameters selected to calculate TCP for chest wall ..............................................26 
5. Parameters selected to calculate NTCP for lung.....................................................27 
6. Parameters selected to calculate NTCP for heart....................................................28 
7. Parameters selected to calculate SCCP for lung. ....................................................30 
8. Parameters selected to calculate SCCP for the contralateral breast........................30 
9. Parameters selected to calculate SCCP for the normal tissue.................................30 
10. Summary of the radiation oncologist plan review ..................................................73 
11. Dmean (Gy) for PTV: Chest Wall (Average + Standard deviation).......................74 
12. D90% – D10% (Gy) for PTV: CW..............................................................................74 
13. Calculated TCP values for CW PTV ......................................................................74 
14. Percent volume of the ipsilateral lung receiving > 20 Gy ......................................75 
15. Calculated NTCP values for radiation pneumonitis ...............................................75 
16. Percent volume of the total lung (ipsilateral + contralateral) > 20 Gy ...................76 
17. Ipsilateral lung’s calculated SCCP values ..............................................................76 
18. Total lung’s calculated SCCP values......................................................................76         
19. Percent volume of the heart receiving > 30 Gy ......................................................77 
20. Percent volume of the heart receiving > 15 Gy ......................................................77 
21. Calculated NTCP values for excess cardiac mortality due to Ischaemic disease      
after radiotherapy....................................................................................................78 
22. Dmean (Gy) for contralateral breast (Average + Standard deviation)....................78 
23. Percent volume of the contralateral breast receiving > 5 Gy..................................78 
 viii 
24. Calculated SCCP values for solid tumor in the contralateral breast after     
radiotherapy ............................................................................................................79 
25. Percent volume of normal tissue (delineated tissue volume except critical structures) 
receiving between 5 and 25 Gy...............................................................................79 
26. Calculated SCCP values for normal tissue .............................................................80 
 
 
                             
 
 ix 
List of Figures 
1. Schematic of helical TomoTherapy unit. The commercially available TomoTherapy 
system does not have an on-board kilo voltage imaging system, rather it uses but have  
a megavoltage CT (Courtesy TomoTherapy Inc. Madison, WI) ..............................2 
2. Conventional electron PMRT technique. The CW and IMN are treated with electron 
beams and the SCl/AX is treated with photon beams...............................................7 
3. Figure 3 shows an example of converting the 90% isodose line (45 Gy) shown in (a) 
to a CW PTV (b).The 45 Gy isodose line, 90% of the prescribed dose, is shown as a 
thick yellow contour. The converted PTV is shown as a solid red area .................16 
4. A dose limiting structure called ring.......................................................................20 
5. A directional blocking structure (Structure is directional blocked, so that no primary 
beam should pass through it before passing through the PTV structure) ...............20 
6. Estimated solid tumors induction as function of homogenous organ dose for normal 
tissue (based on Schneider’s model, Schneider et al 2005a). .................................31 
7. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
supraclavicular nodal region shown on sagittal view (c)........................................35 
8. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
IMN region as shown on the sagittal view (c) .......................................................36 
9. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
chest wall region as shown on the sagittal view (c)................................................38 
10. DVH comparisons for distribution shown in Figures 7 to 9. Solid lines – conventional 
plan, dashed lines –TomoTherapy plan. CW – chest wall target; SCl/AX – 
supraclavicular/axillary target; Ipsi – ipsilateral; Cont – contralateral ...................39 
11. The dDVH of the ipsilateral lung............................................................................41 
12. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
supraclavicular nodal region shown on sagittal view (c)........................................44 
13. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
IMN region as shown on the sagittal view (c) .......................................................45 
14. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
chest wall region as shown on the sagittal view (c)................................................46 
15. DVH comparisons for distribution shown in Figures 12 to 14. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – chest wall target; SCl/AX 
– supraclavicular/axillary target; Ipsi – ipsilateral; Cont – contralateral ................47 
 x 
16. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
supraclavicular nodal region shown on sagittal view (c)........................................51 
17. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
IMN region as shown on the sagittal view (c) .......................................................53 
18. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
chest wall region as shown on the sagittal view (c)................................................54 
19. DVH comparisons for distribution shown in Figures 16 to 18. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – chest wall target; SCl/AX 
– supraclavicular/axillary target; Ipsi – ipsilateral; Cont – contralateral ................55 
20. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
supraclavicular nodal region shown on sagittal view (c)........................................59 
21. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
IMN region as shown on the sagittal view (c) .......................................................61 
22. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
chest wall region as shown on the sagittal view (c)................................................62 
23. DVH comparisons for distribution shown in Figures 20 to 22. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – chest wall target; SCl/AX 
– supraclavicular/axillary target; Ipsi – ipsilateral; Cont – contralateral ................63 
24. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
supraclavicular nodal region shown on sagittal view (c)........................................67 
25. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
IMN region as shown on the sagittal view (c) .......................................................68 
26. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken at the 
chest wall region as shown on the sagittal view (c)................................................69 
27. DVH comparisons for distribution shown in Figures 21 to 23. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – chest wall target; SCl/AX 




Purpose: TomoTherapy, capable of delivering intensity-modulated, image-guided 
radiotherapy with a helical fan-beam, multileaf-collimated beam and detector array 
mounted on a CT ring, is challenging the treatment techniques commonly used in today’s 
radiotherapy clinic. The present works investigates the potential of using TomoTherapy 
in lieu of electron beams for treatment of the chest wall in post-mastectomy radiotherapy 
(PMRT). It is hypothesized that TomoTherapy can plan dose distributions for PMRT 
patients, that a pre-selected radiation oncologist judges to be equal to or better than that 
of a conventional plan treated with electron beams. 
Methods: A patient database of retrospective conventional PMRT treatment plans was 
generated, including contoured target and critical structure region-of-interest volumes. A 
TomoTherapy plan was generated for five patients out of the database using the same 
treatment criteria as the conventional plan. The TomoTherapy plan and the conventional 
plan was evaluated and compared by a radiation oncologist using a simplified scoring 
system. Physical and radiobiological dose metrics were generated from the treatment 
plans to supplement the evaluation of the radiation oncologist. 
Results: Four of the five TomoTherapy plans were rated superior to the rival 
conventional electron beam treatment plan, and the other Tomotherapy plan was rated 
marginally superior. The TomoTherapy plan was able to spare the ipsilateral lung and 
heart of excessive dose as well as the conventional plan, while delivering a more 
homogeneous dose distribution to the target volumes. However, the TomoTherapy plan 
showed the contralateral breast receiving an average dose of 2.9 Gy as opposed to 0.4 Gy 
for the conventional electron beam plan, and a greater volume of normal tissue outside 
 xii 
the target volumes receiving dose between 5 and 25 Gy (average percent volume was 
33% for the TomoTherapy plan and 5 % for the electron beam plan). This could affect 
the radiation oncologist’s decision to use TomoTherapy for younger patients who are at 
greater risk of developing radiation-induced secondary cancers. 
Conclusion: The study showed TomoTherapy can deliver dose distributions the radiation 
oncologist judges to be equal to or better than that of a conventional electron beam 














During the last decade, the radiotherapy clinic has seen numerous advances in 
technology designed to deliver practical and highly conformal dose distribution that 
better spare critical organs while dosing planning PTV volumes (PTVs) to tumorcidal 
levels. Intensity-modulated radiotherapy (IMRT), using multi-leaf collimators and 
advanced 3D treatment planning systems capable of inverse planning, is the most well 
known recent advance in radiotherapy technology (Galvin et al. 2001). IMRT with the 
help of a computerized optimization algorithms provides variable-intensity fields that 
replace uniform intensity ones. Typically, IMRT improves PTV coverage and 
conformality and reduces PTV dose inhomogeneity. The principle of IMRT is to treat a 
patient from a number of different directions (or continuous arcs) with beams of non-
uniform fluences, which have been optimized to deliver a high dose to the PTV volume 
and acceptable low dose to the surrounding normal structures (Khan 2003). 
Tomotherapy is a novel approach to the delivery of IMRT (Mackie et al.  1993). 
Figure 1 shows TomoTherapy Hi-Art System developed by the TomoTherapy Inc. 
(Madison, WI) was designed to provide tomotherapy in a helical motion much like 
current CT machines acquire images. TomoTherapy delivers photon IMRT dose 
distributions with a continuously rotating, helical fan beam using a binary multi-leaf 
collimator, and it utilizes an onboard mega-voltage computerized tomography system 
(MVCT) that allows for image-guided radiotherapy (IGRT). As in an ordinary helical 
computed tomography (CT) scanner, the patient is continuously translated through a ring 
gantry as the fan beam rotates.  
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Figure 1. Schematic of helical TomoTherapy unit. The commercially available 
TomoTherapy system does not have an on-board kilo voltage imaging system, 
rather it uses a megavoltage CT (Courtesy TomoTherapy Inc. Madison, WI) 
TomoTherapy differs from fixed-beam linear accelerator IMRT in several ways. First, 
in fixed-beam IMRT beam directions are selected by the planner before the beam 
intensity patterns are modulated with the optimizer. TomoTherapy uses all beamlet 
orientations within a 40-cm wide fan beam that intersect the PTVs and optimally weights 
them to achieve user-defined volumetric dose goals and limitations. A beamlet is a single 
leaf-pair opening in one projected angle. There are 64 binary leaf-pairs in any projected 
angle and 51 projected angles in each rotation, making a total of 3264 possible beamlets 
in each rotation. This greater degree of freedom on the part of the optimizer in selecting 
beam incidence may allow for improvements in the planning of more complex 
treatments. However, it also may irradiate significant regions of tissue outside the PTV to 
achieve volumetric dose goals unless dose constraints have been placed on those regions. 
Also, the TomoTherapy helical delivery allows the treatment of extended treatment 
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volumes without the need for junctioning fields (Bauman et al. 2005). However, 
TomoTherapy beams are limited to axial beams, i.e., beams directed perpendicular to the 
TomoTherapy gantry axis. 
One obvious difference between a multi-modality linear accelerator and 
TomoTherapy is that the latter does not offer electron beams. Electron beams are 
advantageous in that dose falls rapidly off distal to the treatment volume which makes 
this modality ideal for treating superficial PTVs, often with a single beam. There are a 
multitude of treatment sites that use electrons exclusively or in combination with photon 
beams, especially sites within the breast and head and neck (Tapley 1976 and Hogstrom 
2003a).  
1.2. Significance of TomoTherapy vs. Electron Beams 
Published comparisons between TomoTherapy and mixed beams are limited in 
number. Lock et al. (2002) compared a conventional photon/electron total scalp 
irradiation technique Tung et al. (1993) with a serial tomotherapy treatment delivered 
with the NOMOS MIMiC system.  They concluded that the conventional technique was 
superior in sparing critical structures, such as the eyes, although the tomotherapy 
treatment delivered much greater dose homogeneity to the PTV and provided better 
sparing of the parotid glands. However, the study did not explore the possibility of 
relaxing PTV dose homogeneity to better spare critical structures and achieve a 
comparably similar plan to the conventional irradiation technique. Orton et al. (2005) 
showed that a TomoTherapy dose distribution was superior for treating total scalp due to 
PTV dose homogeneity and sparing of critical structures such as the eyes. 
Superficial lesions (depth < 6cm) have traditionally been treated with the electron 
radiation techniques. Because electrons are directly ionizing particles and deliver high 
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dose on the surface while sparing critical structures due to limited particle range making 
electrons a good candidate to treat superficial PTVs. However for large treatment areas, 
abutting adjacent electron fields can in some circumstances result in either overdosing or 
under dosing the junctioned areas. In Mary Bird Perkins Cancer Center (MBPCC) where 
the project was conducted, shifting the abutment borders during the course of treatment is 
done to minimize dose heterogeneity at field junctions. This requires considerable effort 
in the planning of both field shapes and positions, and requires careful observation of the 
abutment regions during the course of radiotherapy.  
Eliminating problems associated with a field junction is often necessary, especially 
for large, superficial chest wall PTVs in post-mastectomy radiation therapy (PMRT). An 
ideal technique should deliver a homogenous dose to the PTV including the matchline, if 
deemed to be a risk, while minimizing normal tissue radiation exposure without 
compromising the PTV treatment. Although this can be achieved in part with arc therapy 
(Hogstrom 2003a), that technology is complex and not often used.  
Prior studies by Krueger et al. (2003) demonstrated the feasibility and possible utility 
of IMRT for post-mastectomy breast patients. Unlike traditional methods, the IMRT 
technique significantly reduced problems associated with field junctioning and improved 
the dose homogeneity in the chest wall. The natural extension of this technique for 
PMRT is the use of arcing modulated photon beams, and TomoTherapy may seem an 
ideal candidate for this technique. The ability to treat extended treatment volumes 
without the need for fixed-beam field junctioning, and the greater degree of freedom on 
part of the optimizer in selecting beam incidence, may give TomoTherapy an advantage 
over conventional fixed-beam linear accelerator techniques.  
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Although TomoTherapy is a relatively new technology, its presence is being felt 
throughout the radiotherapy community.  When using a new technology, the question of 
improvement in dose delivery, cost, and outcome create a complex environment to 
answer the question: Does the technology significantly improve patient care (Lock et al. 
2002)? This investigation focused on a more specific question: Are TomoTherapy 
treatment plans for PMRT patients comparable to conventional (electron field) technique 
treatment plans? 
 1.3. Postmastectomy Radiation Therapy (PMRT) 
1.3.1. Overview 
Although radiotherapy in the treatment of breast cancer is associated with an ncreased 
risk of complication, subsequent studies showed its advantage in improving cancer 
survival overrides the risks associated with the radiation treatment. Rutqvitst et al. (1990) 
showed that post-operative radiation therapy for early breast cancer produces a sustained 
improvement of recurrence free survival, mainly through prevention of locoregional 
recurrences. Other studies have subsequently shown a significant improvement in 
survival for patients who underwent radiation treatment after surgical mastectomy (Ragaz 
et al. 1997, Overgaard et al. 1997 and 1999). On the basis of these and other studies, a 
National Institutes of Health consensus panel recommended locoregional PMRT in 
patients with > 4 positive axillary lymph nodes and/or T3 and T4 staged lesions (Eifel et 
al. 2000). As a result, many institutions offer comprehensive PMRT for high risk breast 
cancer patients who have undergone mastectomy. 
PMRT PTVs the chest wall (CW) and regional lymph nodes such as the 
supraclavicular (SCl), the internal mammary chain (IMN), and the axillary (AX) nodes. 
Due to the complexity of the treatment, different techniques exist, with no single 
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technique being accepted as a gold standard. Pierce et al. (2002) investigated seven 
commonly used conventional techniques for irradiation of post mastectomy CW patients, 
namely: 1. Standard tangents; 2. Electron fields; 3. Cobalt fields; 4. Reverse hockey stick 
(RHS); 5. 30%/70% Photon/Electron mix; 6. 20%/80% Photon/Electron mix; and 7. 
Partially wide tangent fields (PWTF). The study concluded that none of the techniques 
combined the best CW and IMN coverage with minimal lung and heart complication 
probabilities, i.e., no single technique was found to be superior for all treatment goals. 
However, among the seven discussed techniques, the use of PWTFs was found to 
produce the most appropriate compromise of PTV coverage and normal tissue sparing. 
The study did not take IMRT into consideration. In conclusion, the selection of PMRT 
technique should be based on clinical discretion and technical expertise available to 
implement complex treatment plans. Clinical discretion encompasses estimated risk 
reduction in locoregional recurrence and its potential impact on survival, and the 
predicted complication risk for each patient.  
1.3.2. Conventional Electron PMRT Technique 
In our study, we have chosen to compare TomoTherapy with a conventional electron 
and photon beam technique commonly used to treat PMRT patients at Mary Bird Perkins 
Cancer Center.  In this technique, a total of five fields are typically used (Figure 2). The 
medial CW is treated with an anterior electron field and the lateral CW is treated with an 
oblique electron field. The IMN is treated with an anterior electron field, and parallel-
opposed photon fields (6 MV) are used to treat the region containing the 
supraclavicular/axillary nodes (SCl/AX). As discussed in the previous section, matching 
adjacent electron fields presents a considerable problem for this technique at the border 
of medial and lateral chest-wall fields because converging central axes create a large 
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overlap (Hogstrom 2003a). This problem is addressed in the clinic by moving the 
junction between the lateral and medial fields every week over the typical 5-week course 
of treatment to reduce the magnitude of dose heterogeneity. 
 
Figure 2. Conventional electron PMRT technique. The CW and IMN are treated with 
electron beams and the SCl/AX is treated with photon beams. 
1.3.3. Complications Associated with PMRT 
The close proximity of the lung and heart to the CW and IMN poses problems for 
PMRT. Radiation exposure risks to the heart and to the lung include pericarditis and 
pneumonitis respectively. According to Emami et al. (1991), 50 Gy causes a probability 
of 50 % complication (pericarditis) and 24.5 Gy causes a probability of 50 % 
complication (pneumonitis) within five years. The concern for complication is amplified 
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if patients are likely to receive systemic chemotherapy agents with known cardiac and 
pulmonary toxicity (Krueger et al. 2003). Hence, individual treatment planning warrants 
complex field arrangements that strive to spare critical structures but at the same time 
deliver the prescribed dose to designated treatment areas. 
Biological dose-response models are useful for evaluating plans. Biological dose 
metrics associated with these models include the tumor control probability (TCP), the 
normal tissue complication probability (NTCP) for organs at risk, and the secondary 
cancer complication probability (SCCP). Researchers using available epidemiological 
data have used these models to describe complications associated with radiation therapy. 
However, the values generated by TCP, NTCP and SCCP models should not be used to 
predict absolute biological impact as there is still concern in the scientific community to 
their accuracy (Perez and Brady, 1998). On the other hand, TCP, NTCP and SCCP 
models are useful for comparing rival plans and techniques (Perez and Brady, 1998).  
Gagliardi et al. (1996) demonstrated the relative seriality model (Kallman et al., 
1992) can be used to quantitatively describe the dose response relationship for excess 
cardiac mortality on the basis of given clinical data. The study showed that a dose 
reduction to the heart has more importance than a restriction of the irradiated heart 
volume. In this model, the heart’s functional subunits are regarded as an organ with a 
parallel structure of serially aligned subunits. 
The risk of secondary cancer induction in the contralateral breast is also of concern in 
radiotherapy of breast cancer. Storm et al. (1992) conducted a case-control study in 
cohort of 56,540 women in Denmark diagnosed with invasive breast cancer from 1943 
through 1978. The average age at the time of radiation exposure in this study was 51 
years, and 2.51 Gy was the mean radiation dose to the contralateral breast. The result of 
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their study indicated that the radiation treatment of women with breast cancer does not 
significantly increase the risk of development of contralateral breast cancer. They 
attributed the negative finding to the age at radiation exposure. Most published positive 
findings for radiation-associated risk has been concentrated in young patients, less than 
30 years at time of exposure (Hancock et al. 1993).  
1.3.4. IMRT 
One approach that may solve the problem of normal tissue complications is intensity-
modulated radiation therapy (IMRT).Unlike conventional techniques, IMRT utilizes 
varying intensity beams, which allows more conformal dose delivery to complex PTV 
shapes while limiting dose to nearby critical structures. IMRT has shown to be a 
promising approach in a wide range of disease sites (Khan 2003). An increasing body of 
evidence suggests that IMRT can produce superior conformal treatment plans for head 
and neck, lung, prostate, and other sites. Published comparisons between conventional 
PMRT techniques and IMRT are limited in number. After studying treatment plans for 
ten stage II and III breast cancer patients with left-sided cancers, Krueger et al. (2003) 
concluded that a nine-field IMRT technique achieves full PTV coverage and improved 
dose homogeneity while maintaining similar doses to heart and ipsilateral lung as the 
conventional PWTF technique. In this technique, 6-MV tangential photon fields were 
used to treat the supraclavicular node. Medial and lateral coplanar tangents using 6-MV 
photons were used to treat the chest wall and the internal mammary chain node. The 
inferior medial chest wall was treated with supplemental electrons (6 or 9 MeV). The 
study also showed contralateral lung and breast receive a larger volume of low dose 
compared to the PWTF which may increase the chance of secondary cancer induction. 
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1.4. Hypothesis/Specific Aims 
The hypothesis of current study is that TomoTherapy can plan dose distributions for 
PMRT patients, that a pre-selected radiation oncologist judges to be equal to or better 
than that of a conventional plan treated with electron beams, alone or in combination with 
photon beams. To carry out this objective the following specific aims were followed.  
Aim 1: Generate a patient database. Generate a patient database by selecting patient 
data from five chest wall (CW) patients that were previously-treated with electron 
beams. 
 Aim 2: Plan each case on the TomoTherapy Hi-Art planning system. Specify 
planning objectives and weights for the PTVs and critical structures. Use the system’s 
iterative method to minimize the objective function and produce clinically acceptable 
treatment plan.  
Aim 3: Determine treatment plan metrics. Choose and conduct physical plan 
evaluation metrics for both techniques. Generate dose volume histograms (DVHs) for 
all involved structures. The metrics will include, the minimal, maximal and mean 
dose to the planning PTV volumes (PTVs) and organs at risks (OARs), the volume of 
lung receiving more than 20 Gy (V20lung), the volume of heart receiving more than 30 
Gy (V30heart), and the volume of the contralateral breast receiving more than 5 Gy 
(V5contralateral  breast). This data will be made available for the radiation oncologist’s 
evaluation and comparison of rival plans (Aim 4) as needed, and to further 
supplement the comparisons.   
Aim 4: Clinically evaluate the conventional and TomoTherapy treatment plans. Have 
one American Board Radiology (ABR) certified radiation oncologist evaluate both 
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the TomoTherapy and the conventional treatment plans.  Along with the plans, 
provide multiple choice questionnaires to the radiation oncologist for this evaluation. 
Aim 5: Determine biological treatment plan metrics. Calculate and compare the tumor 
control probability (TCP), the normal tissue complication probability (NTCP), and 
the secondary cancer complication probability (SCCP) for both techniques. The 
purpose of these data is to supplement the comparisons of two rival plans 
(conventional and the TomoTherapy plans) with radiobiological modeling of the 
impact of the treatment.  
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Chapter 2 
Materials and Methods 
  
2.1. Overview of Study 
The first aim was to generate a PMRT patient database on an ADAC Pinnacle 
workstation version 6.2 (Philips, Inc., Milpitas, California). The planning process is 
based on Hogstrom algorithm for an electron treatment planning (Hogstrom et al. 1981b) 
and a superposition-convolution dose calculation engine for photon treatment planning. 
The patient database included the CT scan data, contoured regions of interests (ROIs) 
relevant to the study, and several Pinnacle treatment plan trials for plan comparison 
studies. At least one Pinnacle treatment plan trial contained the original conventional 
treatment plan used to treat the PMRT patient along with the calculated dose distribution. 
The database was made to maintain patient confidentiality in accordance with a protocol 
approved by an institutional review board.  
The second goal was to generate a clinically-acceptable, TomoTherapy treatment plan 
for each case in the PMRT patient database. TomoTherapy Hi-Art System, version 2.1 
(TomoTherapy, Inc, Madison, WI) was used to generate a plan for each of the five 
patients in the PMRT patient database. The planning process is based on a superposition-
convolution dose calculation engine (Mackie et al. 2000) and an iterative least square 
optimization process (Shepard et al. 2000). An iterative process is a process used to 
minimize the objective function after the user specified the planning objectives and 
weights for the PTV and critical structures. As a result, appropriate beam pattern, 
position, and intensity will be calculated by the system. After a suitable plan was 
developed on the TomoTherapy treatment planning system, the dose distribution was 
transferred to the PMRT patient database into a separate Pinnacle treatment plan trial. 
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 The third goal was to generate and compare dose-volume metrics from both the 
TomoTherapy and the conventional electron beam treatment plans.  
 The fourth goal was to have a radiation oncologist evaluate both plans for clinical 
acceptability, i.e., is the plan acceptable for treating the patient? The radiation oncologist 
also was to review both plans side-by-side and determine which plan was better (or if 
they were similar). A questionnaire was generated to help the radiation oncologist in the 
decision process. 
 The fifth goal was to generate and compare the radiobiological impact of the 
PMRT plans using standard radio-biological models. Radiobiological metrics of interest 
in this study included:   
1. PTV tumor control probability (TCP).  
2. normal tissue complication probability (NTCP) for the heart and lung.  
3. secondary cancer complication probability (SCCP) for contralateral and 
ipsilateral lungs, contralateral breast, and for normal tissue.  
2.2. Aim 1: Patient Database 
 A logbook of Pinnacle treatment plans archived since August 2000 maintained by 
MBPCC group was searched for possible chest wall or breast treatment sites. From that 
list 22 patients receiving conventional electron beam PMRT to the chest wall were 
identified. From the 22 patients identified, five were selected for the study; four left-sided 
and one right-sided chest wall PMRT patients. The basis for the five patients chosen were 
(1) they were treated by the same radiation oncologist who was asked to evaluate 
treatment plans for the study, and (2) that the CT scan data was readily available from a 
separate archive maintained by on-site CT technologists. This was important because CT 
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scan data could not be directly exported from a Pinnacle workstation to the TomoTherapy 
planning system. 
 The Pinnacle treatment plan was retrieved and imported into the Pinnacle 
workstation. The patient name and medical record number were stripped from the 
treatment plan and replaced with a code number. The code number was linked to the 
patient name and medical record number on a master list kept independently by the 
project director. This was done to maintain patient confidentiality in accordance with a 
protocol approved by an institutional review board.  
PTVs were generated for each of the PMRT treatment plans in the patient database, 
as (1) PTVs are typically not contoured for conventional electron beam PMRT planning, 
and (2), the TomoTherapy treatment planning system (TPS) is strictly an inverse 
planning system and requires contoured PTVs and OARs.  
All OARs were generated except for the spinal cord which was previously contoured 
in some patients. Both the lungs were contoured separately using Pinnacle’s auto contour 
tool which uses CT thresholds and appropriate edits was made. The heart chambers (left 
and right atria and left and right ventricles) were contoured starting at the superior extent 
of the heart chamber and ending at the apex. The contralateral breast was outlined 
starting at the clavicular head and ending at the inframammary fold. Also, the spinal cord 
and the 0.5 cm expanded spinal cord were outlined. A structure compromising all normal 
tissue, excluding specified OARs and PTVs, was auto-contoured. This was defined by 
subtracting the volumes of PTVs and specified normal tissues from the whole patient 
volume. The entire contour set was reviewed by a certified dosimetrist and later by the 
radiation oncologist upon reviewing the dose distributions.   
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Since the prescribed dose for the chest wall (CW) can differ from prescribed dose for 
the supraclavicular and axillary (SCl/AX) nodes, separate PTVs are required for 
TomoTherapy treatment planning. Therefore, two PTVs were generated, one for the CW 
and the IMN, and a second for the supraclavicular/axillary nodes (SCl/AX). The IMN 
was considered part of the CW PTV because the dose prescriptions for each were the 
same in each of the patient cases.  
The PTVs were generated from the conventional Pinnacle treatment plans by 
converting an isodose line to a contour. The isodose line chosen for generating a PTV 
was 90% of the prescribed dose. The prescribed dose in each case was the maximum dose 
delivered to water along the central axis. In order to separate the two PTVs, the 
prescription for SCl/AX was set to zero when contouring CW and vice versa. Pinnacle 
allows turning individual prescription assigned to filed(s) on/off, when a multiple 
prescriptions present in a treatment plan. As a result, the dose distribution from individual 
fields can easily be seen. If the automatically-generated PTV was found broken up into 
several contours on the same slice resulting in “contour islands,” the PTV contours were 
connected if found in close proximity to each other. PTV contours that protruded into 
OARs delineating the lung and the heart were pushed outside of the contour delineating 
the OAR.  
Figure 3 shows an example of converting the 90% isodose line to a contour for the 
CW PTV. Figure 3a shows the Pinnacle-calculated dose distribution of the conventional 
plan for the CW. The prescribed dose was 50 Gy to 100% of the dose at R100 along the 
central axis of each beam. Note the CW PTV in Figure 3b has excluded the ipsilateral 
lung, which is an organ at risk.  
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a)   
b)  
Figure 3 shows an example of converting the 90% isodose line (45 Gy) shown in (a) to a 
CW PTV (b).The 45 Gy isodose line, 90% of the prescribed dose, is shown as a 
thick yellow contour. The converted PTV is shown as a solid red area 
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2.3. Aim 2: TomoTherapy PMRT Treatment Plans 
2.3.1. Importing CT Data 
The TomoTherapy treatment planning system was used to generate an inverse IMRT 
plan for 5 patients. CT scan data was imported into the TomoTherapy treatment planning 
20workstation from the CT workstation (GE Discovery ST, Model #: 316097CN5) after 
being retrieved from long term storage. Patient name and medical record number were 
removed and changed to a code before sending CT images to the TomoTherapy planning 
system.  CT image slices, which were 5-cm or more beyond the superior and inferior 
extent of the PTVs and did not include OARs, were removed from the CT scan data to 
reduce dose calculation times with TomoTherapy treatment planning. The CT scan data 
was down-sampled to a smaller matrix size (128 x 128 matrix) as it was imported into the 
Tomotherapy treatment planning system. The diameter of the CT scan data field-of-view 
was 50 cm. Hence, the pixel width of the down-sampled CT image was 3.91 mm. The 
slice width of the CT scan data in all patient studies was 2.5 mm. 
2.3.2. TomoTherapy Dose Prescription 
Planning ROIs (PTVs and OARs) were transferred from the Pinnacle workstation to 
the TomoTherapy planning system. The CW PTV was selected as the primary PTV to 
receive the TomoTherapy dose prescription. The TomoTherapy dose prescription is 
specified in terms of percentage volume and dose, i.e., the percentage volume of the 
primary PTV that receives at least the prescribed dose. The TomoTherapy dose 
prescription for the CW was specified to be 50 Gy (same as conventional plan), and the 
percentage volume that received 50 Gy or less was set to match the percentage volume of 
the CW in the conventional plan that received 50 Gy or less.  
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2.3.3. TomoTherapy Plan Parameters 
Table 1 gives a summary of the plan parameter values used for TomoTherapy 
treatment planning. To achieve better dose conformality to the PTV in the superior-
inferior direction of the patient, the small jaw opening (2.45 cm) was used instead of the 
large jaw opening (4.98 cm). The pitch, i.e., the fraction of the field width advanced with 
each revolution, was set to a standard value of 0.3 used in the clinic. The planning 
modulation factor, the ratio of the highest beamlet intensity to the average intensity of all 
non-zero beamlets, was set to a maximum of 7 to allow for significant intensity 
modulation. The dose grid resolution was set to “fine” making the dimensions of the dose 
grid equivalent to the voxel dimensions of the CT scan data (3.91 x 3.91 x 2.5 mm
3
).  
Table 1. TomoTherapy plan parameter specifications  
Field width 2.45 cm 
Pitch 0.3 
Planning modulation factor 7 




2.3.4. Dose Limiting Structures  
Quite often, dose limiting structures were utilized to better control the TomoTherapy 
dose distribution. The most common dose limiting structures used was a “ring” (Figure 4) 
surrounding a PTV, which is also widely utilized for IMRT treatment planning on 
conventional linear accelerators. Several treatment planning trials were performed to 
study the effect of using “ring” dose limiting structures on TomoTherapy. The contour 
expands and contract option on the Pinnacle system was used to auto-contour rings. The 




1. A temporary ROI was generated by expanding the PTV by 1 cm in all 
directions. 
2. Another temporary ROI was generated by expanding the PTV by 1.5 cm in all 
directions. 
3. The final “ring” ROI was generated by subtracting the first ROI from the 
second. 
The ring dose limiting structures were labeled as region at risk (RAR) for TomoTherapy 
treatment planning.  
Other dose limiting structures were utilized in the TomoTherapy treatment plan as 
needed. A dose limiting structure which acts as a buffer zone was drawn approximately 
one cm superiorly and inferiorly from the PTVs to limit patient dose outside the PTVs. A 
directional blocking RAR was utilized to prevent beamlets from coming in the direction 
where patient anatomy was outside the CT scan field of view (FOV) Figure 5.  
2.3.5. TomoTherapy Optimization and Dose Calculation 
Once all such constraints were defined, optimization and dose calculation 
commenced. Table 2 lists typical PTV and RAR constraints upon completion of 
optimization. Dose constraints such as importance levels and maximum/minimum 
penalties were specified to all structures (PTVs and RARs). Compared to distal critical 
structures, a large value was used for the importance and max dose penalty for adjacent 
ones. In general, OARs dose limits were made as low as possible without degrading dose 
delivered to the PTV or creating unnecessary dose to large volumes of normal tissue. 
Also dose to normal tissue peripheral to PTVs was minimized without degrading PTV 




Figure 4. A dose limiting structure called ring 
 
Figure 5. A directional blocking structure (Structure is directional blocked, so that no 






Table 2. Typical PTV (a) and RAR (b) constraints upon completion of optimization.  
(a) 


















CW 100 53 100 50 50 50 250 
SC/AX 1200 55 1000 50 50 48 5 
(b) 






DVH   









15 14 30 5 5 700 
Ips. Lung 21 45 1000 40 5 50000 
Cont. 
Breast 
22 3 150 50 1 2000 
Heart 16 27 50 20 5 1000 
Exp. Cord 8 3 100 10 2 40 
Ring 13 48 10000 45 15 400 
 
A plan using TERMA (Total Energy Released per unit Mass) optimization mode was 
used to generate an estimate of dose deposited from photon interaction. TERMA dose 
algorithm allows for fast optimization but does not convolve the dose spread kernel with 
the TERMA interaction point along the central ray of a beamlet. After adjusting the dose 
constraint parameters and modifying dose limiting structures (RARs), the plan was 
further optimized using BEAMLET optimization mode to obtain the most accurate dose 
distribution. Optimization with the beamlet dose algorithm is much more time consuming 
but the resultant dose distribution is more accurate as it does convolve the dose spread 
kernel with the TERMA interaction point. On the other hand, BEAMLET optimization 
takes significant amount of time since the dose distribution from individual beamlets has 
to be calculated on the first iteration.  
Fractionation was applied in all five cases, once an acceptable dose distribution 
was generated to verify that the TomoTherapy machine could deliver such a treatment. 
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Fractionation is dividing up the patient’s dose prescription into a number of different 
sessions, all of which add up to the total prescribed dose. The temporary dose distribution 
file (EOPDose.img) was saved along with the header file into a separate directory on the 
TomoTherapy workstation and was exported to a separate Pinnacle plan trial in the 
patient database.  
2.4. Aim 3: Generate Dose-Volume Treatment Plan Metrics 
 Dose-volume treatment plan metrics were generated using (1) ADAC Pinnacle, 
(2) Matlab version 7.1 (MathWorks, Inc., Natick, Massachusetts), and (3) Microsoft 
office excel 2003 (Microsoft, Inc., Redmond, Washington). The Pinnacle treatment plan 
trial dose-volume information was exported to the in-house program as an RTOG file. 
Differential dose-volume histograms (dDVHs) embedded in the RTOG file were read in 
by the in-house program to generate relevant dose-volume metrics. The dose-volume 
metrics of interest in this study included: 
1. DVHs for each PTV and OAR. 
2. Mean and standard deviation of dose to each PTV. 
3. Difference in PTV dose between 10% and 90% of PTV (D90%-D10%). 
4. Volume of lung receiving at least 20 Gy or more. 
5. Volume of heart receiving at least 30 Gy or more. 
6. Volume of heart receiving at least 15 Gy or more. 
7. Volume of contralateral breast receiving at least 5 Gy or more. 
8. Mean dose to the contralateral breast.  
 Both the standard deviation of the PTV and the D90%-10% , the difference between 
the dose received by 90% of the PTV volume and the dose received by 10% of the PTV 
volume.. The percent of the total lung volume exceeding 20 Gy (V20lung) to be 
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statistically significant relative to the development of pneumonitis. Hence, the volume of 
lung receiving at least 20 Gy or more was useful in comparing competing treatment plans 
to evaluate the risk of pneumonitis (Graham et al., 1999). Studies conducted by Gagliardi 
et al. (1996) showed that the probability of excess cardiac mortality due to IHD is less 
than 4.5% for the whole heart volume receiving less than 30 Gy. Hence, the percentage of 
heart that received 30 Gy or less (V30heart) was chosen to compare competing treatment 
plans. 
 Table 3 lists the dose/volume limits specific to our clinic. Published tolerance 
doses and irradiated volumes (Emami, et al. 1991) are generally higher those listed on 
Table 3.  Radiation oncologists at our institution have stricter dose limits than published 
tolerance doses, which they feel take into account the patient’s prior experience, such as 
chemotherapy. The radiation oncologist specifications were taken into consideration 
during optimizing the TomoTherapy treatment plans. Also, the volume of the 
contralateral breast that received 5 Gy or more (V5contralateral breast), the volume of the heart 
that received 15 Gy or more (V15heart), and the volume of the lung that received 20 Gy or 
more (V20lung) were noted when generating the dose-volume treatment plan metrics. 
Table 3. Radiation oncologist specifications 
Organ Dose Limit Volume 
Lung 20 Gy < 15% 
Heart 15 Gy < 10%   
Spinal Cord 10 Gy < 10% 
Contralateral Breast Max 5 Gy   
 
2.5. Aim 4: Radiation Oncologist Evaluation of Treatment Plans 
 In the fourth aim, a radiation oncologist evaluated and compared both 
conventional and TomoTherapy plans. The radiation oncologist was presented with a 
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side-by-side trial comparison of the patient dose distribution and DVHs of both the 
conventional and TomoTherapy plans on a Pinnacle workstation. The actual worksheet 
provided to the radiation oncologist is located in Appendix A. First, the radiation 
oncologist was asked to evaluate the clinical acceptability of each plan on a scale of 1 to 
5, 1 being best (acceptable) and 5 being worst (unacceptable). Second, the radiation 
oncologist was asked to rate the TomoTherapy plan in comparison with the conventional 
plan on a scale of 1 to 5, 1 being best (superior) and 5 being worst (inferior).  The 
radiation oncologist was then asked to fill out a simple multiple-choice question as to 
why he preferred a particular plan. Third, a margin was left on questionnaire for 
additional comments. 
2.6. Aim 5: Determine Biological Treatment Plan Evaluation Tools  
An “in-house” radiation biological program developed by Dr. Tae Ku Lee, research 
medical physicist, was used to calculate and compare relevant radiobiological treatment 
plan evaluation tools. The radiobiological evaluation tools included:  
1. PTV tumor control probability (TCP).  
2. Normal tissue complication probability (NTCP) for the heart and lung.  
3. Secondary cancer complication probability (SCCP) for the both the 
contralateral and ipsilateral lungs, contralateral breast, and for normal tissue.  
Differential dose-volume histograms (dDVHs) embedded in the RTOG file were 
imported into the in-house program to evaluate radiobiological treatment plans. 
2.6.1. Tumor Control Probability (TCP) 
TCP, the probability of tumor control in radiation therapy, for the chest wall PTV was 
calculated using the Webb and Brenner model [Webb and Nahum 1993 and Brenner et al. 
1993], which incorporates a repair mechanism. Sinceα , β  and Tr values for chest wall 
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are not available in literature, chest wall was considered as a breast to retrieve α  and β  
values and as a skin to retrieve the Tr value. Definitions ofα , β  and Tr parameters are 
listed on the following page. The overall probability of tumor control is the product of 




iTCPTCP .    (1) 
The tumor control probability in each tumor sub-volume is calculated as   
    
iSFN
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*−= ,    (2) 
N in Equation 2 is the product of the number of tumor cells per cm
3
 (n) and the volume vi 
that receives dose Di, i.e.     
N = ∑
i
ivn .     (3) 
SF in Equation 2, the survival fraction (i.e., the probability of cell survival from 
irradiation), is given by 
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G, the dose protraction factor for radiation-induced DNA damage repair, in the Equation 
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where λR, repair rate (hr
-1
), is calculated as 





=λ .      (6) 
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The rest of the parameters in Equations 4, 5, and 6 defined as: 
α  = cell radio sensitivity (Gy-1). 
β  = the effectiveness/lethality of radiation (Gy-2). 
di = Di/number of fraction (Gy/fraction). 
T = treatment time per fraction (hr). 
Tr = Repair half-time of cells with sub lethal damage (hr). 
The values of the parameters used to calculate TCP for the chest wall are shown in Table 
4. 
Table 4. Parameters selected to calculate TCP for chest wall 
Name Value Source 
 N 2 .0 E 8 cm
-3 
[Wigg et al. 2001] 
 α  0.51 Gy-1 [Wigg et al. 2001] 
β  0.061 Gy-2 [Wigg et al. 2001] 
T 1/3 hrs Each treatment time is approximated to 20 
minutes (Wang et al. 2003) 
Tr 1.6 hrs [Wigg 2001] 
 
2.6.2. Normal Tissue Complication Probability (NTCP) for The Lung 
Since lung has a strong dose-volume tissue complication response, it is considered 
a parallel structure. The NTCP for lung was calculated using Layman-Kutcher-Burman 
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Deff  is biological mean dose called effective dose (Warkentin et al. 2004). The other 
parameters in Equations 7, 8, and 9 are defined as: 
n  = a fitting parameter that accounts for the dose-volume dependence of tissue  
iv  = is volume ratio (volume that receives Di / total volume of the structure) 
m = a fitting parameter that control the slope of the dose repose curve 
D50 = the dose at which there is a 50% chance of complication (Gy) within 5yrs 
i   =the number of individual bins in the differential DVH data.  
Radiation pneumonitis was used as an end point for the current study. The parameters 
used to calculate NTCP are listed on Table 5. 
Table 5. Parameters selected to calculate NTCP for lung. 
Name Value Source 
N 0.87
 
[Pierce et al. 2002] 
M 0.18 [Pierce et al. 2002] 
D50 24.5 Gy [Emani et al. 1991] 
 
2.6.3. Normal Tissue Complication Probability (NTCP) for The Heart 
The heart has a low dose-volume complication response, but can be damaged with 
high dose in small volumes. Therefore, it is appropriate to model it as a serial structure 
like the spinal cord. The relative seriality model, developed by Kallman et al. (1992), was 
used to calculate NTCP for the whole heart structure. Cardiac mortality due ischaemic 
heart disease (IHD) was used as an end point for the current study. NTCP using the 











−−= ,    (10) 












 ,    (11) 
 28 
 
where: P (D) = the NTCP of the organ irradiated homogenously to dose Di 
iv  = is volume ratio (volume that receives Di / total volume of the structure) 
m = a fitting parameter that control the slope of the dose repose curve 
D50 = the dose at which there is a 50% chance of complication (Gy) 
s = seriality of subunits (ratio of number of serial subunits to all subunits) 
γ   = The maximum relative slope of the dose response curve 
i     = the number of individual bins in the differential DVH 
The parameters used to calculate NTCP are listed on Table 6.  
Table 6. Parameters selected to calculate NTCP for heart. 
Name Value Source 
D50 52.3 Gy [Gagliardi et al. 1996] 
S 1.0 [Gagliardi et al. 1996] 
γ 1.28 [Gagliardi et al. 1996] 
 
2.6.4. Secondary Cancer Complication Probability (SCCP) for The Lung. 
The probability of secondary cancer induction  was calculated for lung, contralateral 
breast, and normal tissue using the Schneider model [Schneider et al. 2005a and 2005b]:  
orgorgorg OEDInSCCP *=  ,    (12) 
     

















The parameters of Equations 12 and 13 are listed below: 
α  = Cellular radio sensitivity (Gy -1). 
Inorg = Absolute cancer incidence provided by the International Commission on 
Radiological Protection (ICRP 60) and the United Nation Scientific 
Committee on the Effects of Atomic Radiation (UNSCEAR). 
 N= is dose calculation point 
 i = the number of individual bins in the differential DVH. 
D = dose (Gy). 
The parameter values used to calculate SCCP for lung are listed in Table 7. The Inorg 
for lung (data is from UNSCEAR) is for the total lung (ipsilateral and contralateral lung). 
Hence, the individual ipsilateral and contralateral lungs’ SCCP values were corrected by 
multiplying the calculated SCCP values with the respective volume ratio.  The residual 
life expectancy that was used to find the life time SCCP for lung was taken as the 
difference between the female life expectancy (79.8 yrs) Arias et al.,(2003) and the onset 
age of female patients diagnosis for breast cancer (45 yrs) (SEER, 2006). 
The parameter values used to calculate SCCP for the contralateral breast and the 
normal tissue are listed in Table 8 and 9 respectively.  The Inorg values (data is from ICRP 
60) for both the contralateral breast and the normal tissue are given in life-time risk (50-
yrs) in percent. The Inorg for normal tissue (Table 9) is taken from the atomic bomb 
survivors (whole body irradiation). Hence, normal tissue’s SCCP value for each patient 
was corrected by multiplying the calculated SCCP values with the respective volume 
ratio.  The average woman’s volume in cm
3
 was calculated assuming an average weight 




Table 7. Parameters selected to calculate SCCP for lung. 
Name Value Source 
α   0.129Gy-1 [Schneider et al. 2005a] 
Inorg  8.27/(10
4
. patients. yr. Gy) [Schneider et al. 2005a] 
Table 8. Parameters selected to calculate SCCP for the contralateral breast.  
Name Value Source 
α   0.085 Gy-1 [Schneider et al. 2005b] 
Inorg  0.78 (% Gy
-1
) [Schneider et al. 2005b] 
Table 9. Parameters selected to calculate SCCP for the normal tissue. 
Name Value Source 
α   0.085 Gy-1 [Schneider et al. 2005b] 
Inorg  1.76 (% Gy
-1
) [Schneider et al. 2005b] 
 
Figure 6 shows a plot of cancer incidence per 10
4
 patients per year for solid tumor 
(i.e., an abnormal mass tissue that usually does not contain cysts or liquid areas) 
induction as a function of dose. Note that the probability is maximum around 11 Gy and 
decreases for higher dose values because sterilization of already mutated cells becomes 
more important. According to the Schneider’s model, certain tissue receiving dose 
between 5 and 25 Gy will have a high probability of solid tumors  induction (> 0.75) with 
a mean follow up time of 9.5yrs. Therefore, the volume of normal tissue receiving doses 
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Figure 6. Estimated solid tumors induction as function of homogenous organ dose for 







3.1. Format for Presenting Results of Each Patient 
The format for presenting the results is the same for all patients. For each patient, the 
results are presented in the following order: 
1. isodose comparison,  
2. DVH comparison, 
3. radiation oncologist’s review of the conventional and TomoTherapy plans, and 
their comparison, 
4. mean and standard deviation of dose to the chest wall PTV, and the resultant TCP, 
5. dose to the ipsilateral lung and heart, and the resultant NTCPs, and 
6. dose to the contralateral breast and normal tissue, and the resultant SCCPs. 
The isodose comparisons between the conventional and TomoTherapy plans are 
shown on transverse CT image slices for three distinct regions: 
1. The supraclavicular nodal region along the beam axis of the parallel-opposed 
photon beams used in the conventional plan. 
2. The region of the chest wall containing the internal mammary chain nodes. 
3. A region of the chest wall inferior to (2). 
The transverse CT image slice where the isodose comparison is made is delineated by 
a yellow line in a sagittal midline CT image view in the same figure as the isodose 
comparison. The isodose lines are displayed in Gy, with dose values of 55, 50, 45, 35, 25, 
15, and 5 Gy. In addition, due to change in the prescription for the supraclavicular and 
axillary nodal region, an additional 40.5 Gy dose line is added for the third and fifth 
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patients and 43.2 Gy dose line is added for the fourth patient. The color scheme for the 
isodose lines is consistent for all patients. It should be noted that the TomoTherapy TPS 
calculates dose in air outside the patient while ADAC Pinnacle TPS sets this dose to zero. 
This results in isodose lines appearing outside the patient in the TomoTherapy plan. 
A cumulative DVH comparison between the conventional and TomoTherapy plans is 
done for both planning PTVs (chest wall and supraclavicular/axillary nodes) and for the 
heart, ipsilateral lung, contralateral breast, and normal tissue. In these plots, the y-axis 
displays the percentage of the total volume of each region of interest; the x-axis displays 
in Gray.  DVHs for both plans are superimposed on one plot for each patient, with a 
consistent color and line scheme for all patients.  
3.2. Patient One 
A 74 year old female was diagnosed to have an infiltrating ductal carcinoma of the 
upper outer quadrant of the left breast, stage T2pN3aM0 carcinoma with 10 out of 12 
lymph nodes positive with extra-nodal extension. The conventional electron beam PMRT 
plan had the following fields: 
1. AP/PA 6 MV photon beam SCl/AX fields,  
2. 12 MeV electron beam IMN field, 
3. 9 MeV electron beam medial CW field, and 
4. 9 MeV electron beam lateral CW field.  
Both the SCl/AX and CW PTVs were irradiated to 50 Gy in 25 fractions. 
3.2.1. Isodose Comparison  
Figure 7 shows the isodose comparison between the conventional plan (Figure 7a) 
and the TomoTherapy plan (Figure 7b) on the transverse CT image slice in the region of 
the supraclavicular nodes delineated by the yellow line in sagittal midline CT image 
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shown in Figure 7c. The yellow 45-Gy isodose line represents the 90% isodose line 
where the TomoTherapy plan was optimized to match the conventional plan. The 
conventional plan showed a hot spot of 55 Gy (110% of the prescription dose) in the 
medial, anterior portion of the dose distribution, whereas the TomoTherapy plan showed 
no similar hot spot in that region.  
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the parallel-opposed photon beams of the conventional plan. 
Greater dose restriction outside the supraclavicular PTV in the TomoTherapy plan during 
optimization might have resulted in a sharper dose falloff along the “beam edges” 
delineated by the conventional plan. The TomoTherapy plan also showed a significant 
volume of tissue outside the PTV receiving low dose (5 Gy or more).However, the 
TomoTherapy plan showed a greater dose gradient beyond the 45 Gy isodose line in the 
anterior-to-posterior (AP) direction. This resulted in lower dose to region posterior to the 
supraclavicular nodes, including the scapula.  
Figure 8 shows the dose distribution for the conventional plan (Figure 8a) and the 
TomoTherapy plan (Figure 8b) on a transverse CT image slice in the region of the IMN 
delineated by the yellow line in sagittal image shown in Figure 8c. The yellow 45 Gy 
isodose line represents the 90% prescription isodose line, where the TomoTherapy plan 
was optimized to match the conventional plan. The conventional plan showed a hot spot 
of 55 Gy (110% of the prescription dose) in the IMN region and at the junction of the 
lateral and medial electron fields. Although in practice this hot spot is reduced (smeared) 




     
Figure 7. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken 
at the supraclavicular nodal region shown on sagittal view (c).  
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Figure 8. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken 
at the IMN region as shown on the sagittal view (c).  
Figure 9 shows the isodose comparison between the conventional plan (Figure 9a) 
and the TomoTherapy plan (Figure 9b) on a transverse CT image slice near the inferior 
border of the CW PTV, and is delineated by the yellow line in sagittal midline CT image 
shown in Figure 9c. The yellow 45 Gy isodose line represents the 90% isodose line, 
where the TomoTherapy plan was optimized to match the conventional plan. The 
conventional plan showed a hot spot of 55 Gy (110% of the prescription dose at the 
junction of the lateral and medial electron fields. Although in practice this hot spot is 
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reduced by moving (smeared) the match line, this is not reflected in the conventional 
plan. 
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the electron beams for the IMN and the lateral chest wall of the 
conventional plan. Greater dose restriction outside the chest wall PTV in the 
TomoTherapy plan during optimization might have resulted in a sharper dose falloff 
along the “beam edges” delineated by the conventional plan. The TomoTherapy plan also 
showed a significant volume of tissue outside the PTV receiving low dose (5 Gy or 
more). However, the TomoTherapy plan showed a greater dose gradient beyond the 45 
Gy isodose line in the anterior-to-posterior (AP) direction. This resulted in a lower 
volume with dose greater than 20 Gy to ipsilateral lung.  
3.2.2. DVH Comparisons  
The DVH comparisons are shown in Figure 10. The conventional plan showed a 
small volume of the PTV receiving high dose created by the junction of the medial and 
lateral chest wall, although in practice this hot spot is reduced by moving (smeared) the 
junction over the course of treatment. For the TomoTherapy plan, dose homogeneity was 
better than the conventional plan for both the SCl/AX and CW PTVs. However, low dose 
(D < 5Gy) covered a larger volume of normal tissue. 
Compared to the conventional plan, the TomoTherapy plan showed less ipsilateral 
lung volume receiving doses greater than 13 Gy while more ipsilateral lung volume 
received doses less than 13 Gy. This crossover of DVH lines for OARs was seen in all 
patients so it will be reported as the crossover dose from here on out. The crossover dose 
for the heart was 15 Gy. 
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Figure 9. Transverse views of the conventional plan (a) and TomoTherapy plan (b) taken 
at the chest wall region as shown on the sagittal view (c).  
3.2.3. Radiation Oncologist Review 
 A radiation oncologist evaluated the clinical acceptability of both conventional and 
TomoTherapy plans and scored both plans acceptable. After reviewing the dose 
distributions and DVHs for both plans, he ranked the TomoTherapy plan marginally 
superior. PTVs (CW and SCI/AX) coverage was listed as a reason for preferring 
TomoTherapy plan over the conventional plan. The radiation oncologist commented that 
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the dose to the heart was higher in the TomoTherapy plan and may be of concern if the 
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Figure 10. DVHs comparison for distribution shown in Figures 7 to 9. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – chest wall PTV; 
SCl/AX – supraclavicular/axillary PTV; Ipsi – ipsilateral; Cont – contralateral 
3.2.4. Chest Wall 
The TomoTherapy plan showed a more uniform CW PTV dose, e.g. the standard 
deviation (σ) of the CW PTV dose on the TomoTherapy plan was lower than that for the 
conventional plan. The average CW dose (+ 1σ) was 49.6 + 0.9 Gy on the TomoTherapy 
plan and 50.7 + 6 Gy on the conventional plan. The D90%-10% of the CW volume was 
9.8 Gy for the conventional plan and 1.4 Gy for the TomoTherapy plan. Even though the 
CW PTV dose distribution showed better uniformity on the TomoTherapy plan, the TCP 
values were comparable for both plans (conventional plan = 0.978 and TomoTherapy 
plan = 0.995).  
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3.2.5. Ipsilateral Lung 
During optimization of the TomoTherapy plan, a high penalty factor was assigned to 
the ipsilateral lung objective to force photon beams to come in an oblique direction. As a 
result, TomoTherapy avoided irradiating it with high doses (20Gy). The ipsilateral lung 
receiving dose above 20 Gy was reduced from 16.1% on the conventional plan to 9.1% 
on the TomoTherapy plan. The ipsilateral lung in the conventional plan was exposed to 
higher doses (e.g. 5% of the ipsilateral lung received 40 Gy or more). However, as shown 
in Figure 10, a large volume of the ipsilateral lung received low dose (5 Gy or more) with 
the TomoTherapy plan. The average ipsilateral lung dose (+ 1σ) was comparatively 
higher on the TomoTherapy plan (conventional plan = 9.4 + 12.5 Gy and TomoTherapy 
plan = 11.3 + 6.0 Gy). The reason behind high standard deviation of the conventional 
plan is due to asymmetric distribution of dose to the ipsilateral lung, shown in Figure 11. 
A relatively higher NTCP value was observed for the TomoTherapy plan although both 
values were small (conventional plan = 0.0007 and TomoTherapy plan = 0.0016). 
3.2.6. Heart 
The heart volume receiving a dose above 30 Gy or more was very low and similar in 
both plans (0.06% for the TomoTherapy plan and 0.54% for the conventional plan). Also, 
similar was the value for V15heart (conventional plan = 4.3% and TomoTherapy plan = 
4.5%). Like the ipsilateral lung, a larger volume of the heart received low dose (5 Gy or 
more) with the TomoTherapy plan. The average heart dose (+ 1σ) was reduced from 7.3 
+ 3.6 Gy on the TomoTherapy plan to 3.5 + 5.0 Gy on the conventional plan. A relatively 
lower NTCP value was observed for the TomoTherapy plan although both values were 
























Figure 11. The dDVH of the ipsilateral lung.   
3.2.7. Contralateral Breast 
 In order to stop dose exposure to the contralateral breast, a higher importance factor 
was assigned compared to other critical structures during optimization of the 
TomoTherapy plan (Table 2). This helped to bring down the dose to the contralateral 
breast. However, due to the nature of beam arrangements of TomoTherapy delivery, dose 
to the contralateral breast was significantly greater than the dose for conventional plan. 
The average contralateral breast dose (+ 1σ) was 3.2 + 1.6 Gy on the TomoTherapy plan 
and 0.1 + 0.1 Gy for the conventional plan. As shown in Figure 9, a relatively large 
volume of the contralateral breast was exposed to low dose with the TomoTherapy plan. 
The percent of volume receiving 5 Gy or more was zero for the conventional plan and 
13.1 for the TomoTherapy plan. Age dependence effect of radiation induced breast 
cancer was ignored when calculating SCCP for patient one (age = 73 yrs). The SCCP was 
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relatively higher for the TomoTherapy plan (conventional plan = 0.0001 and 
TomoTherapy plan = 0.0178).   
3.2.8. Normal Tissue 
The normal tissue volume receiving between 5 and 25 Gy for this patient was 17.6 
cm
3
 for the conventional plan and 111.7 cm
3
 for the TomoTherapy plan. The calculated 
SCCP value relatively higher on the TomoTherapy plan (conventional plan =0.003 and 
TomoTherapy plan = 0.012).   
3.3. Patient Two 
A 53 – year old female was diagnosed to have an infiltrating ductal carcinoma of the 
upper outer quadrant of the left breast, stage T3pN2aM0 carcinoma with 4 out of 12 
lymph nodes positive with extra-nodal extension. The conventional electron beam PMRT 
plan had the following fields: 
1. AP/PA 6 MV photon beam SCl/AX fields,  
2. 12 MeV electron beam IMN field, 
3. 6 MeV electron beam medial CW field, and 
4. 9 MeV electron beam lateral CW field. 
Both the SCl/AX and CW PTVs were irradiated to 50 Gy in 25 fractions. 
3.3.1. Isodose Comparison  
Figure 12 shows the isodose comparison between the conventional plan (Figure 12a) 
and the TomoTherapy plan (Figure 12b) on the transverse CT image slice in the region of 
the supraclavicular nodes delineated by the yellow line in sagittal midline CT image 
shown in Figure 12c. The yellow 45 Gy isodose line represents the 90% isodose line 
where the TomoTherapy plan was optimized to match the conventional plan. The 
conventional plan showed a hot spot of 55 Gy (110% of the prescription dose) in the 
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medial, anterior portion of the dose distribution, whereas the TomoTherapy plan showed 
no similar hot spot in that region.  
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the parallel-opposed photon beams of the conventional plan. 
Greater dose restriction outside the supraclavicular PTV in the TomoTherapy plan during 
optimization might have resulted in a sharper dose falloff along the “beam edges” 
delineated by the conventional plan. The TomoTherapy plan also showed a significant 
volume of tissue outside the PTV receiving low dose (5 Gy or more).However, the 
TomoTherapy plan showed a greater dose gradient beyond the 45 Gy isodose line in the 
AP direction. This resulted in lower dose to region posterior to the supraclavicular nodes, 
including the scapula.  
Figure 13 shows the isodose comparison on the transverse slice for the conventional 
plan (Figure 13a) and the TomoTherapy plan (Figure 13b) on a transverse CT image slice 
in the region of the IMN delineated by the yellow line in sagittal image shown in Figure 
13c. The yellow 45 Gy isodose line represents the 90% prescription isodose line, where 
the TomoTherapy plan was optimized to match the conventional plan. The conventional 
plan showed a hot spot of 55 Gy (110% of the prescription dose) in the IMN region and 
at the junction of the lateral and medial electron fields.  
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the electron beams for the IMN and the lateral CW of the 
conventional plan. Greater dose restriction outside the CW PTV in the TomoTherapy 
plan during optimization might have resulted in a sharper dose falloff along the “beam 
edges” delineated by the conventional plan. The TomoTherapy plan also showed a 
significant volume of tissue outside the PTV receiving low dose (5 Gy or more). 
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However, the TomoTherapy plan showed slightly greater dose gradient beyond the 45 Gy 
isodose line in the AP direction. This resulted in lower volume of dose to ipsilateral lung.  
 
     
Figure 12. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the supraclavicular nodal region shown on sagittal view (c).  
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Figure 13. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the IMN region as shown on the sagittal view (c).  
Figure 14 shows the isodose comparison between the conventional plan (Figure 14a) 
and the TomoTherapy plan (Figure 14b) on the transverse CT image slice near the 
inferior border of the CW PTV, and is delineated by the yellow line in sagittal midline 
CT image shown in Figure 14c. The yellow 45 Gy isodose line represents the 90% 
isodose line, where the TomoTherapy plan was optimized to match the conventional plan. 
The conventional plan showed a hot spot of 55 Gy (110% of the prescription dose) and at 
the junction of the lateral and medial electron fields.  
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The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the medial and the lateral CW of the conventional plan. Unlike 
the conventional plan, the TomoTherapy plan avoided irradiating the ipsilateral lung with 
high dose (45, 50, and 55 Gy). However, the TomoTherapy plan also showed a 
significant volume of tissue outside the PTV receiving low dose (5 Gy or more).   
 
   
Figure 14. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the CW region as shown on the sagittal view (c).  
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3.3.2. DVH Comparisons  
The DVH comparisons are shown in Figure 15. The conventional plan showed a 
small volume of the PTV receiving high dose created by the junction of the medial and 
lateral CW. For the TomoTherapy plan dose homogeneity was better than the 
conventional plan for both the SCl/AX and CW PTVs. However, low dose (5 Gy or 
more) covered a larger volume of the normal tissue not including critical structures. The 
crossover dose for the ipsilateral lung was 4.3 Gy, and the crossover dose for the heart 
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Figure 15. DVH comparisons for distribution shown in Figures 12 to 14. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – CW PTV; SCl/AX – 
supraclavicular/axillary PTV; Ipsi – ipsilateral; Cont – contralateral 
3.3.3. Radiation Oncologist Review 
A radiation oncologist evaluated the clinical acceptability of both conventional and 
TomoTherapy plans and scored the conventional plan marginally acceptable and the 
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TomoTherapy plan acceptable. After reviewing the dose distributions and DVHs for both 
plans, he ranked the TomoTherapy plan superior. The absence of hot and cold spots on 
the TomoTherapy plan was listed as a primary reason for preferring TomoTherapy plan 
over the conventional plan.  
3.3.4. Chest Wall 
The TomoTherapy plan showed a more uniform dose distribution. The average CW 
dose (+ 1σ) was 49.9 + 1.1 Gy on the TomoTherapy plan and 51.4 + 6.1 Gy on the 
conventional plan. Dose irradiating 90% to 10% of the CW volume was 13.6 Gy for the 
conventional plan and was 2.3 Gy for the TomoTherapy plan. Although the CW PTV 
dose distribution showed  better uniformity on the TomoTherapy plan, TCP values were 
comparable for both plans (conventional plan = 0.989 and TomoTherapy plan = 0.996).  
3.3.5. Ipsilateral Lung 
During optimization of the TomoTherapy plan, high penalty factor was assigned to 
the ipsilateral lung objective to force photon beams to come in an oblique direction. As a 
result, compared to the conventional plan, the TomoTherapy plan showed less volume 
irradiated. The ipsilateral lung receiving dose above 20 Gy was reduced from 29.4% for 
the conventional plan to 24.8% for the TomoTherapy plan. Also unlike the TomoTherapy 
plan, the ipsilateral lung was exposed to high doses with the conventional plan (e.g. 5% 
of the ipsilateral lung received 40 Gy or more).  The average ipsilateral lung dose (+ 1σ) 
was comparatively lower on the TomoTherapy plan (conventional plan = 14.7 + 16.2 Gy 
and TomoTherapy plan = 12.3 + 12.6 Gy). A relatively lower NTCP value was calculated 
for the TomoTherapy plan although both values were insignificant (conventional plan = 
0.025 and TomoTherapy plan = 0.005). 
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3.3.6. Heart 
The heart volume receiving a dose above 30 Gy or more was very low (0.02% for the 
TomoTherapy plan and 0.9% for the conventional plan). The heart volume receiving 15 
Gy or more was slightly higher on the TomoTherapy plan (conventional plan = 4.6% and 
TomoTherapy plan = 6.8%). As shown on Figure 15, large volume of the ipsilateral lung 
received low dose (2.5 Gy) with the TomoTherapy plan compared to the conventional 
plan. The average heart dose (+ 1σ) was reduced from 5.1 + 4.8 Gy on the conventional 
plan to 3.9 + 5.6 Gy on the TomoTherapy plan. A relatively lower NTCP value was 
calculated for the TomoTherapy plan although both values were insignificant 
(conventional plan = 0.0018 and TomoTherapy plan = 0.0003). 
3.3.7. Contralateral Breast 
The average contralateral breast dose (+ 1σ) was 2.1 + 1.4 Gy on the TomoTherapy 
plan and 0.1 + 0.1 Gy on the conventional plan. As shown in the DVH comparison, a 
large volume of the contralateral breast was exposed to low dose (2 Gy) with the 
TomoTherapy plan. Also, the percent of volume receiving 5 Gy or more on the 
conventional plan was 0.0% and 3.0% on the TomoTherapy plan. Age dependence effect 
of radiation induced breast cancer was ignored when calculating SCCP for patient two 
(age = 53 yrs). The calculated SCCP value was relatively higher on the TomoTherapy 
plan (conventional plan 0.0003 and TomoTherapy plan = 0.0125).   
3.3.8. Normal Tissue 
The normal tissue volume receiving between 5 and 25 Gy for this patient was 11.6 
cm
3
 for the conventional plan and 61.9 cm
3
 on the TomoTherapy plan. The calculated 
SCCP value was relatively higher on the TomoTherapy plan (conventional plan = 0.002 
and TomoTherapy plan 0.008).   
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3.4. Patient Three 
A 49-year old female was diagnosed to have a squamous cell carcinoma of the upper 
outer quadrant of the left breast, stage T2N1M0 carcinoma with 2 out of 10 lymph nodes 
positive with extra-nodal extension. The conventional electron beam PMRT plan had the 
following fields: 
1. AP/PA 6 MV photon beam SCl/AX fields, 
2. 9 MeV electron beam IMN field, 
3. 9 MeV electron beam medial CW field, and 
4. 9 MeV electron beam lateral CW field. 
The prescription for the CW was 50 Gy in 25 fractions. The prescription for the SCl/AX 
was 45 Gy in 25 fractions. 
3.4.1. Isodose Comparison  
Figure 16 shows the isodose comparison between the conventional plan (Figure 16a) 
and the TomoTherapy plan (Figure 16b) on the transverse CT image slice in the region of 
the supraclavicular nodes delineated by the yellow line in sagittal midline CT image 
shown in Figure 16c. The yellow green 40.5 Gy isodose line represents the 90% 
prescription isodose line where the TomoTherapy plan was optimized to match the 
conventional plan. Compared to the conventional plan, the TomoTherapy plan showed 
small area covered by hot spot of 50 Gy (110% of the prescription dose). 
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the parallel-opposed photon beams of the conventional plan. 
Greater dose restriction outside the supraclavicular PTV in the TomoTherapy plan during 
optimization might have resulted in a sharper dose falloff along the “beam edges” 
delineated by the conventional plan. The TomoTherapy plan also showed a significant 
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volume of tissue outside the PTV receiving low dose (5 Gy or more). However, the 
TomoTherapy plan showed a greater dose gradient beyond the 40.5 Gy isodose line in 
AP direction. This resulted in lower dose to region posterior to the supraclavicular nodes, 
including the left upper lobe of lung.  
 
   
Figure 16. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the supraclavicular nodal region shown on sagittal view (c).  
Figure 17 shows the isodose comparison the conventional plan (Figure 17a) and the 
TomoTherapy plan (Figure 17b) on a transverse CT image slice in the region of the IMN 
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delineated by the yellow line in sagittal image shown in Figure 17c. The yellow 45 Gy 
isodose line represents the 90% prescription isodose line, where the TomoTherapy plan 
was optimized to match the conventional plan. The conventional plan showed a hot spot 
of 55 Gy (110% of the prescription dose) at the junction of the lateral and medial electron 
fields. Although in practice this hot spot is reduced (smeared) by moving the match line, 
this is not reflected in the conventional plan. 
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the electron beams for the IMN and the lateral CW of the 
conventional plan. The physical location of the IMN, in between the contralateral and 
ipsilateral lung at a depth of approximately 2 – 5.5 cm  from the surface made it difficult 
for the TomoTherapy trying to cover this region with a photon beam. As a result, dose 
bleeding toward aorta was observed throughout all five cases. Also, the TomoTherapy 
plan showed a significant volume of tissue outside the PTV receiving low dose (5 Gy or 
more). 
Figure 18 shows the isodose comparison between the conventional plan (Figure 18a) 
and the TomoTherapy plan (Figure 18b) on the transverse CT image slice near the 
inferior border of the CW PTV, and is delineated by the yellow line in sagittal midline 
CT image shown in Figure 17c. The yellow 45 Gy isodose line represents the 90% 
isodose line, where the TomoTherapy plan was optimized to match the conventional plan. 
The conventional plan showed a hot spot of 55 Gy (110% of the prescription dose) at the 
junction of the lateral and medial electron fields. Although in practice this hot spot is 




   
Figure 17. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the IMN region as shown on the sagittal view (c).  
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Figure 18. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the CW region as shown on the sagittal view (c).  
The conventional plan showed a sharper dose falloff than that of the TomoTherapy 
plan along the beam edges of the medial and the lateral CW of the conventional plan. 
Greater dose restriction outside the CW PTV in the TomoTherapy plan during 
optimization might have resulted in a sharper dose falloff along the “beam edges” 
delineated by the conventional plan. The TomoTherapy plan also showed a significant 
volume of tissue outside the CW PTV receiving low dose (5 Gy or more). Both the 
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conventional and TomoTherapy plans showed similarity when it comes to sparing the 
lung and heart. 
3.4.2. DVH Comparisons  
The DVH comparisons are shown in Figure 19. The conventional plan showed small 
volume of the PTV receiving high dose created by the junction of the medial and lateral 
CW. For the TomoTherapy plan, dose homogeneity was better than the conventional plan 
for both the SCl/AX and CW PTVs. However, low dose (5 Gy or more) covered a larger 
volume of the normal tissue not including critical structures. The crossover dose for the 
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Figure 19. DVH comparisons for distribution shown in Figures 16 to 18. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – CW PTV; SCl/AX – 
supraclavicular/axillary PTV; Ipsi – ipsilateral; Cont – contralateral 
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3.4.3. Radiation Oncologist Review 
A radiation oncologist evaluated the clinical acceptability of both conventional and 
TomoTherapy plans and scored both plans acceptable. After reviewing the dose 
distributions and DVHs for both plans, he ranked the TomoTherapy plan superior. No 
comment was provided on his decision. 
3.4.4. Chest Wall 
The TomoTherapy plan showed an improved uniform dose distribution. The average 
CW dose (+ 1σ) was 49.7 + 1.9 Gy on the TomoTherapy plan and 52.4 + 7.0 Gy on the 
conventional plan. Dose irradiating 90% to 10% of the CW volume was 14.3 Gy on the 
conventional plan and was 4.2 Gy for the TomoTherapy plan. Even though the CW PTV 
dose distribution showed better uniformity on the TomoTherapy plan,  the TCP values 
were similar for both plans (conventional plan = 0.989 and TomoTherapy plan = 0.991).  
3.4.5. Ipsilateral Lung 
The TomoTherapy plan showed less volume of ipsilateral lung irradiated. The 
ipsilateral lung receiving dose above 20 Gy was reduced from 28.4% on the conventional 
plan to 22.0% on the TomoTherapy plan. Also unlike the TomoTherapy plan, the 
ipsilateral lung was exposed to high doses with the conventional plan (e.g.  5% of the 
ipsilateral lung received 40 Gy or more).  The average ipsilateral lung dose (+ 1σ) was 
comparatively lower on the TomoTherapy plan (conventional plan = 14.0 + 17.7 Gy and 
on the TomoTherapy plan = 11.5 + 13.3 Gy). A relatively lower NTCP value was 
calculated for the TomoTherapy plan although both values were small (conventional plan 
= 0.02 and TomoTherapy plan = 0.0031). 
 57 
3.4.6. Heart 
The heart volume receiving above 30 Gy or more was similar for both plans (2.2% for 
the TomoTherapy plan and 2.5% for the conventional plan). Also similar was the heart 
volume receiving 15 Gy or more (conventional plan = 12 % and TomoTherapy plan = 
12.1 %). As shown on Figure 19 large volume of the ipsilateral lung received low dose 
(2.5 Gy) with the TomoTherapy plan compared to the conventional plan. A higher 
average heart dose (+ 1σ) was observed in the TomoTherapy plan (conventional plan = 
5.6 + 8.0 Gy and TomoTherapy plan = 7.1 + 7.05 Gy). The NTCP values were the same 
for both plans (conventional plan = 0.004 and TomoTherapy plan = 0.004). 
3.4.7. Contralateral Breast 
The average contralateral breast dose (+ 1σ) was 2.1 + 0.8 Gy for the TomoTherapy 
plan while 0.1 + 0.1 Gy for the conventional plan. As shown on in Figure 19, relatively 
large volume of the contralateral breast was exposed to low dose (2 Gy) with the 
TomoTherapy plan compared to the conventional plan. Also, the percent of volume 
receiving 5 Gy or more was similar on both plans (conventional plan = 0% and 
TomoTherapy plan = 0.9%). Age dependence effect of radiation induced breast cancer 
was ignored when calculating SCCP for patient three (age = 49 yrs). The calculated 
SCCP value was relatively higher on the TomoTherapy plan (conventional plan = 0.0004 
and TomoTherapy plan = 0.0131).  
3.4.8. Normal Tissue 
The normal tissue volume receiving dose between 5 and 25 Gy was 9.2 cm
3
 on the 
conventional plan and 52.4 cm
3
 on the TomoTherapy plan. The calculated SCCP value 
per year was relatively higher for the TomoTherapy plan (conventional plan = 0.002 and 
TomoTherapy plan = 0.007).   
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3.5. Patient Four 
A 39 – year old female was diagnosed to have an infiltrating ductal carcinoma of the 
upper outer quadrant of the left breast, stage T3pN2aM0 carcinoma with 9 out of 12 
lymph nodes positive with extra-nodal extension. The conventional electron beam PMRT 
plan had the following fields: 
1. AP/PA 6 MV photon beam SCl/AX fields,  
2. 12 MeV electron beam IMN field, 
3. 9 MeV electron beam medial CW field, and 
4. 9 MeV electron beam lateral CW field.  
The prescription for the CW was 50 Gy in 25 fractions. The prescription for the SCl/AX 
was 48.25 Gy in 25 fractions. 
3.5.1. Isodose Comparison  
Figure 20 shows the isodose comparison between the conventional plan (Figure 20a) 
and the TomoTherapy plan (Figure 20b) on the transverse CT image slice in the region of 
the supraclavicular nodes delineated by the yellow line in sagittal midline CT image 
shown in Figure 20c. The yellow green 43.4 Gy isodose line represents the 90% 
prescription isodose line where the TomoTherapy plan was optimized to match the 
conventional plan. The conventional plan showed a hot spot of 55 Gy (110% of the 
prescription dose) in the medial, anterior portion of the dose distribution, whereas the 
TomoTherapy plan showed a lower hot spot of 50 Gy (104% of the prescription dose) in 
that region. Unlike the conventional plan, the TomoTherapy plan avoided irradiating the 
ipsilateral lung with high dose (45 Gy). 
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the parallel-opposed photon beams of the conventional plan. The 
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TomoTherapy plan also showed a significant volume of tissue outside the PTV receiving 
low dose (5 Gy or more).  
 
   
Figure 20. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the supraclavicular nodal region shown on sagittal view (c).  
Figure 21 shows the isodose comparison for the conventional plan (Figure 21a) and 
the TomoTherapy plan (Figure 21b) on a transverse CT image slice in the region of the 
IMN delineated by the yellow line in sagittal image shown in Figure 21c. The yellow 45 




plan was optimized to match the conventional plan. The Conventional plan showed a hot 
spot of 55 Gy (110% of the prescription dose) at the junction of the lateral and medial 
electron fields.  
The conventional plan showed a sharper dose falloff than that of the TomoTherapy 
plan along the beam edges of the electron beams for the IMN and the lateral CW of the 
conventional plan. Higher dose near the aorta was observed in the TomoTherapy plan. 
The TomoTherapy plan showed a significant volume of tissue outside the PTV receiving 
low dose (5 Gy or more). 
Figure 22 shows the isodose comparison between the conventional plan (Figure 22a) 
and the TomoTherapy plan (Figure 22b) on the transverse CT image slice near the 
inferior border of the CW PTV, and is delineated by the yellow line in sagittal midline 
CT image shown in Figure 22c. The yellow 45 Gy isodose line represents the 90% 
isodose line, where the TomoTherapy plan was optimized to match the conventional plan. 
The conventional plan showed a significant region of tissue receiving 55 Gy (110% of the 
prescription dose).  
The conventional plan showed a sharper dose falloff than that of the TomoTherapy 
plan along the beam edges of the medial and the lateral CW of the conventional plan. The 
TomoTherapy plan showed a significant volume of tissue outside the PTV receiving low 
dose (5 Gy or more).   
3.5.2. DVH Comparisons  
The DVH comparisons are shown in Figure 23. The conventional plan showed a 
small volume of the PTV receiving high dose created by the junction of the medial and 
lateral CW. Although in practice this hot spot is reduced by moving (smeared) the match 
line. For the TomoTherapy plan showed dose homogeneity was better than the 
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conventional plan for both the SCl/AX and CW PTVs. However, low dose (5Gy or more) 
covered a large area of contralateral breast, contralateral lung, and the normal tissue not 
including critical structures. The crossover dose for the ipsilateral lung was 16 Gy. The 
crossover dose for the heart was 8.6 Gy. 
 
   
Figure 21. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the IMN region as shown on the sagittal view (c). 
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Figure 22. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
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Figure 23. DVH comparisons for distribution shown in Figures 20 to 22. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – CW PTV; SCl/AX – 
supraclavicular/axillary PTV; Ipsi – ipsilateral; Cont – contralateral 
3.5.3. Radiation Oncologist Review 
A radiation oncologist evaluated the clinical acceptability of both conventional and 
TomoTherapy plans and scored the conventional plan marginally acceptable and the 
TomoTherapy plan acceptable. After reviewing the dose distributions and DVHs for both 
plans, he ranked the TomoTherapy plan superior. Better PTV coverage and fewer hot 
spots on the TomoTherapy plan was listed as a primary reason for preferring 
TomoTherapy plan over the conventional plan.  
3.5.4. Chest Wall 
The TomoTherapy plan showed an improved uniform dose distribution. The average 
CW dose (+ 1σ) was 50.4 + 1.5 Gy on the TomoTherapy plan and 54.0 + 7.5 Gy on the 
conventional plan. Dose irradiating 90% to 10% of the CW volume was 12.5 Gy for the 
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conventional plan and was 3.0 Gy for the TomoTherapy plan. Even though, the CW PTV 
dose distribution showed better uniformity on the TomoTherapy plan, the TCP values 
were similar for both plans (conventional plan = 0.996 and TomoTherapy plan = 0.997).  
3.5.5. Ipsilateral Lung 
Compared to the conventional plan, the TomoTherapy plan avoided exposing the 
ipsilateral lung with high doses (45 Gy).  However, as shown in Figure 23, a large 
volume of the ipsilateral lung received low dose (5 Gy or more) with the TomoTherapy 
plan. Similar values for V20lung was observed for both plans (conventional plan = 23.9% 
and TomoTherapy plan = 22.8%).  The average ipsilateral lung dose (+ 1σ) was 
comparatively lower on the TomoTherapy plan (conventional plan = 13.3 + 16.7 Gy and 
TomoTherapy plan = 12.7 + 12.7 Gy). A relatively smaller NTCP value was observed for 
the TomoTherapy plan although both values were insignificant (conventional plan = 
0.0117 and TomoTherapy plan = 0.0059). 
3.5.6. Heart 
The heart receiving dose above 30 Gy or more was reduced from 6.8% on the 
conventional plan to 4.1% on the TomoTherapy plan. The heart volume receiving 15 Gy 
or more was reduced from 17.1% on the conventional plan to 14.5% on the 
TomoTherapy plan. However, as shown in Figure 23, a large volume of the heart 
received low dose (2.5 Gy) with the TomoTherapy plan. Comparable average heart dose 
(+ 1σ) was observed in both plans (conventional plan = 8.5 + 10.7 Gy and TomoTherapy 
plan = 9.1 + 7.7 Gy). A lower NTCP value was calculated for the TomoTherapy plan 
(conventional plan = 0.020 and TomoTherapy plan = 0.007). 
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3.5.7. Contralateral Breast 
Dose to the contralateral breast was significantly higher in the TomoTherapy plan 
than in the conventional plan. The average contralateral breast dose (+ 1σ) was 3.8 + 2.8 
Gy on the TomoTherapy plan while 0.7 + 0.5 Gy on the conventional plan. As shown in 
Figure 23, a large volume of the contralateral breast was exposed to low dose (2 Gy) with 
the TomoTherapy plan. Large difference was observed for the percent of volume 
receiving 5 Gy or more (conventional plan = 0.0% and TomoTherapy plan = 30.6%). Age 
dependence effect of radiation induced breast cancer was ignored when calculating SCCP 
for patient four (age = 39 yrs). The calculated SCCP value was relatively higher for the 
TomoTherapy plan (conventional plan = 0.0046 and TomoTherapy plan = 0.0183). 
3.5.8. Normal Tissue 
The normal tissue volume receiving between 5 and 25 Gy for this patient was 32.7 
cm
3
 for the conventional plan and 89.1 cm
3
 on the TomoTherapy plan. The calculated 
SCCP value was relatively higher for the TomoTherapy plan (conventional plan = 0.004 
and TomoTherapy plan = 0.009). 
3.6. Patient Five 
A 49 – year old female was diagnosed to have an infiltrating ductal carcinoma of the 
upper outer quadrant of the left breast, stage T1scpN1M0 carcinoma with 2 out of 19 
lymph nodes positive with extra-nodal extension. The conventional electron beam PMRT 
plan had the following fields: 
1. AP/PA 6 MV photon beam SCl/AX fields, 
2. 12 MeV electron beam IMN field, 
3. 9 MeV electron beam medial CW field, and 
4. 9 MeV electron beam lateral CW field.  
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The prescription for the CW was 50 Gy in 25 fractions. The prescription for the SCl/AX 
was 45 Gy in 25 fractions. 
3.6.1. Isodose Comparison  
Figure 24 shows the isodose comparison between the conventional plan (Figure 24a) 
and the TomoTherapy plan (Figure 24b) on the transverse CT image slice in the region of 
the supraclavicular nodes delineated by the yellow line in sagittal midline CT image 
shown in Figure 24c. The yellow green 40.5 Gy isodose line represents the 90% 
prescription isodose line where the TomoTherapy plan was optimized to match the 
conventional plan. Unlike the TomoTherapy plan, the conventional plan showed large 
area covered by hot spot of 50 Gy (110% of the prescription dose). 
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the parallel-opposed photon beams of the conventional plan. The 
TomoTherapy plan also showed a significant volume of tissue outside the PTV receiving 
low dose (5 Gy or more). 
Figure 25 shows the isodose comparison between the conventional plan (Figure 25a) 
and the TomoTherapy plan (Figure 25b) on a transverse CT image slice in the region of 
the IMN delineated by the yellow line in sagittal image shown in Figure 25c. The yellow 
green 40.5 Gy isodose line represents the 90% prescription isodose line, where the 
TomoTherapy plan was optimized to match the conventional plan. The conventional plan 
showed a hot spot of 55 Gy (110% of the prescription dose) at the junction of the lateral 





      
Figure 24. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the supraclavicular nodal region shown on sagittal view (c).  
The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the electron beams for the IMN and the lateral CW of the 
conventional plan. TomoTherapy showed more dose in the region of the aorta. Also, the 
TomoTherapy plan showed a significant volume of tissue outside the PTV receiving low 
dose (5 Gy or more). 
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Figure 25. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the IMN region as shown on the sagittal view (c).  
Figure 26 shows the isodose comparison between the conventional plan (Figure 26a) 
and the TomoTherapy plan (Figure 26b) on the transverse CT image slice near the 
inferior border of the CW PTV, and is delineated by the yellow line in sagittal midline 
CT image shown in Figure 26c. The yellow 45 Gy isodose line represents the 90% 
isodose line, where the TomoTherapy plan was optimized to match the conventional plan. 
The conventional plan showed a hot spot of 55 Gy (110% of the prescription dose) at the 
junction of the lateral and medial electron fields.  
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The conventional plan showed a sharper dose falloff than the TomoTherapy plan 
along the beam edges of the medial and the lateral CW of the conventional plan. The 
TomoTherapy plan showed a significant volume of tissue outside the PTV receiving low 
dose (5 Gy or more).   
 
   
Figure 26. Transverse views of the conventional plan (a) and TomoTherapy plan (b) 
taken at the CW region as shown on the sagittal view (c).  
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3.6.2. DVH Comparisons  
Figure 27 shows the DVH comparisons between the conventional and TomoTherapy 
plan. The conventional plan showed small volumes of the PTV receiving high dose 
created by the junction of the medial and lateral CW. For the TomoTherapy plan, dose 
homogeneity was better than the conventional plan for both the SCl/AX and CW PTVs. 
However, low dose (5Gy or more) covered a larger volume of the normal tissue not 
including critical structures. The crossover dose for the ipsilateral lung was 19 Gy. The 
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Figure 27. DVH comparisons for distribution shown in Figures 24 to 26. Solid lines – 
conventional plan, dashed lines –TomoTherapy plan. CW – CW PTV; SUP/AX – 
supraclavicular/axillary PTV; Ipsi – ipsilateral; Cont – contralateral 
3.6.3. Radiation Oncologist Review 
A radiation oncologist evaluated the clinical acceptability of both conventional and 
TomoTherapy plans and scored the conventional plan marginally acceptable and the 
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TomoTherapy plan acceptable. After reviewing the dose distributions and DVHs for both 
plans, he ranked the TomoTherapy plan superior. Better PTVs (CW and SCl/AX) 
coverage and fewer doses to the critical structure on the TomoTherapy plan was listed as 
a primary reason for preferring TomoTherapy plan over the conventional plan.  
3.6.4. Chest Wall 
The TomoTherapy plan showed improved dose homogeneity in the CW. The average 
CW dose (+ 1σ) was 50.4 + 1.7 Gy on the TomoTherapy plan and 52.0 + 5.2 Gy on the 
conventional plan. Dose irradiating 90% to 10% of the CW volume was 9.0 Gy on the 
conventional plan and was 3.5 Gy on the TomoTherapy plan. The TCP values were 
similar for both plans (conventional plan = 0.990 and TomoTherapy plan = 0.993).  
3.6.5. Ipsilateral Lung 
The TomoTherapy plan avoided exposing the ipsilateral lung with high doses (45 
Gy).  However, as shown in Figure 27, a large volume of the ipsilateral lung received low 
dose (5 Gy or more) with the TomoTherapy plan. Comparable V20lung was observed for 
both plans (conventional plan = 9.5% and TomoTherapy plan = 9.2%).  The ipsilateral 
lung dose (+ 1σ) was lower for the TomoTherapy plan (conventional plan = 7.4 + 10.2 
Gy and TomoTherapy plan = 8.5 + 8.0 Gy). A lower NTCP value was calculated for the 
TomoTherapy plan (conventional plan = 0.0001 and TomoTherapy plan = 0.0002).  
3.6.6. Heart 
In this patient the heart is not a proximal critical structure because the CW PTV is 
located on the right side of the patient’s anatomy. The heart volume receiving above 30 
Gy or more was similar for both plans (0.1% on the TomoTherapy plan and 0.4% on the 
conventional plan). The heart volume receiving 15 Gy or more was reduced from 4.1 % 
on the conventional plan to 1.9 % on the TomoTherapy plan. The average heart dose (+ 
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1σ) was 5.2 + 3.0 Gy on the TomoTherapy plan and 4.2 + 4.4 Gy on the conventional 
plan. The calculated NTCP slightly higher with the TomoTherapy plan (conventional 
plan = 0.0005 and TomoTherapy plan = 0.0002). 
3.6.7. Contralateral Breast 
Dose to the contralateral breast was significantly higher in the TomoTherapy plan 
than in the conventional plan. The average contralateral breast dose (+ 1σ) was 3.6 + 1.9 
Gy on the TomoTherapy plan while 0.8 + 0.8 Gy on the conventional plan. As shown in 
Figure 27, a large volume of the contralateral breast was exposed to low dose (2 Gy) with 
the TomoTherapy plan. The percent volume receiving 5 Gy or more on the conventional 
plan was 0% and 15.9% for the TomoTherapy plan. Age dependence effect of radiation 
induced breast cancer was ignored when calculating SCCP for patient five (age = 49 yrs). 
The calculated SCCP value was relatively higher on the TomoTherapy plan 
(conventional plan = 0.0047 and TomoTherapy plan = 0.0191).   
3.6.8. Normal tissue 
The normal tissue volume receiving between 5 and 25 Gy for this patient was 45.7 
cm
3
 for the conventional plan and 108.0 cm
3
 on the TomoTherapy plan. The calculated 
SCCP was higher for the TomoTherapy plan (conventional plan = 0.006 and 
TomoTherapy plan =0.014). 
3.7. Summary: Tables of Review   
Table 10 shows the summary of the radiation oncologist review of the treatment 
plans. In all cases both plans were scored to be acceptable for treating the patient, and 




Table 10. Summary of the radiation oncologist plan review 




Conv. Vs. Tomo Reason for 
preferring Tomo 
over Conv.  
1 Acceptable  Acceptable  Marginally* Superior Better PTV coverage; 




Acceptable Superior Absence of  hot or 
cold spot 
3 Acceptable Acceptable Superior No comment  
4 Marginally 
Acceptable 
Acceptable Superior Better PTV coverage; 
less hot spot 
5 Marginally 
Acceptable 
Acceptable Superior Better PTV coverage; 
less dose to the 
critical structure 
*Dose to the heart in the TomoTherapy plan was a concern if probability that the 
patient was to receive chemotherapy.  
 
3.7.1. Chest Wall 
Table 11 lists the mean dose and the standard deviation of dose distribution in the 
CW PTV for each of the treatment plans. Table 12 lists the D90%-D10% for the CW PTV. 
Both tables show improved dose homogeneity in the CW PTV with the TomoTherapy 
plan. A Paired Student ‘t’ test was used for plan comparisons using the values listed on 
Table 12. There exist a significant difference in the D90%-D10% for the CW PTV between 
the conventional and the TomoTherapy plans (p = 0.001). Paired Student ‘t’ test is a 
statistical analysis method used to evaluate if there exist an actual difference between two 
small sets of quantitative data when data in each sample set are related. The difference is 
statistically significant (95% confidence level), if the value of p (probability) < 0.05. On 
the other hand, the difference is not statically significant, if the value of p > 0.05 (Press et 
al. 1986). The average value (+ 1σ) was reduced from 11.8 + 2.3 Gy on the conventional 
plan to 2.9 + 1.1 Gy on the Tomotherapy plan.  
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Table 11. Dmean (Gy) for PTV: CW (Average + Standard deviation) 
Patient  Conventional TomoTherapy 
1 50.7 + 6.0 49.6 + 0.9 
2 51.4 + 6.1 49.9 + 1.1 
3 52.4 + 7.0 49.7 + 1.9 
4 54.0 + 7.5 50.4 + 1.5 
5 52.0 + 5.2 50.4 + 1.7 
 
Table 12. D90% – D10% (Gy) for PTV: CW 
Patient  Conventional TomoTherapy 
1 9.8 1.4 
2 13.6 2.3 
3 14.3 4.2 
4 12.5 3.0 
5 9.0 3.5 
 
Table 13 lists the TCP values of the CW PTV for all patients. There was a slight, but 
insignificant difference in the calculated TCP values for CW PTV between the 
conventional and the TomoTherapy plans (p = 0.11).The average TCP value (+ 1σ) on 
the conventional plan was 0.988 +0.007 and 0.994 + 0.002 on the TomoTherapy plan.  
Table 13. Calculated TCP values for CW PTV  
Patient Conventional TomoTherapy 
1 0.978 0.995 
2 0.989 0.996 
3 0.989 0.991 
4 0.996 0.997 
5 0.990 0.993 
 
3.7.2. Lung  
Table 14 lists the V20lung for the ipsilateral lung. There was a statistically significant 
difference in the ipsilateral lung volume receiving > 20 Gy between the conventional and 
the TomoTherapy plans (p = 0.05). The average value (+ 1σ) of the V20lung for the 
conventional plan was 21.5 +8.5 % and 17.6 + 7.8 % for the TomoTherapy plan.  
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Table 14. Percent volume of the ipsilateral lung receiving > 20 Gy  
Patient Conventional TomoTherapy 
1 16.1 9.1 
2 29.4 24.8 
3 28.4 22.0 
4 23.9 22.8 
5 9.5 9.2 
 
Table 15 lists the calculated NTCP values for the ipsilateral lung. There was no 
significant differences in the NTCP between the conventional and the TomoTherapy 
plans (p = 0.13).The average of the NTCP (+ 1σ) on the conventional plan was 0.012 + 
0.011 and 0.003 + 0.002 on the TomoTherapy plan.  
 Table 15. Calculated NTCP values for radiation pneumonitis 
Patient  Conventional TomoTherapy 
1 0.0007 0.0016 
2 0.0250 0.0049 
3 0.0200 0.0031 
4 0.0117 0.0059 
5 0.0001 0.0002 
 
Table 16 shows the V20lung for the total lung (ipsilateral + contralateral) volume. 
Three out of the five patients listed had V20lung values that were higher than the clinical 
limit of 15%. There was no significant differences in the volume receiving > 20 Gy 
between the conventional and the TomoTherapy plans (p = 0.4). The average of the 
V20lung (+ 1σ) on the conventional plan was 12.4 + 4.2 % and 11.4 + 3.3 % on the 
TomoTherapy plan.  
Table 17 lists the calculated SCCP values for the ipsilateral lung. There was 
significant differences in the SCCP between the conventional and the TomoTherapy 
plans (p = 0.005).The average of the SCCP (+ 1σ) on the conventional plan was 0.021 + 
0.007 and 0.029 + 0.008 on the TomoTherapy plan.  
 76 
Table 16. Percent volume of the total lung (ipsilateral + contralateral) > 20 Gy  
Patient  Conventional TomoTherapy 
1 9.9 7.8 
2 17.8 15.1 
3 15.2 12.1 
4 11.8 13.8 
5 7.2 8.2 
  
Table 17. Ipsilateral lung’s calculated SCCP values  
Patient  Conventional TomoTherapy 
1 0.020 0.033 
2 0.019 0.025 
3 0.014 0.023 
4 0.019 0.024 
5 0.032 0.041 
 
Table 18 lists the calculated SCCP values for the total lung. There was significant 
differences in the SCCP between the total and the TomoTherapy plans (p = 0.004).The 
average SCCP value (+ 1σ) on the conventional plan was 0.032 + 0.012 and 0.062 + 
0.010 on the TomoTherapy plan.  
 Table 18. Total lung’s calculated SCCP values  
Patient  Conventional TomoTherapy 
1 0.028 0.073 
2 0.025 0.046 
3 0.019 0.059 
4 0.038 0.067 
5 0.049 0.066 
 
3.7.3. Heart 
Table 19 lists the value of V30heart. Since the heart is not in a proximal distance to the 
CW PTV for the last patient, the fifth patient’s V30heart, V15heart and NTCP were not 
considered when calculating either a paired Student’s T test or the overall average. There 
was a difference, although statistically insignificant, in the volume receiving > 30 Gy 
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between the conventional and the TomoTherapy plans (p = 0.14). The average heart 
volume receiving dose above or equal to 30 Gy (+ 1σ) was reduced from 2.7 +2.9 % on 
the conventional plan to 1.6 + 2.0 % on the TomoTherapy plan.  
Table 19. Percent volume of the heart receiving > 30 Gy  
Patient Conventional TomoTherapy 
1 0.54 0.06 
2 0.9 0.02 
3 2.5 2.2 
4 6.8 4.1 
5 0.4 0.1 
 
Table 20 lists the value of V15heart. Both the conventional and the TomoTherapy plans 
showed values of V15heart higher than the clinical limit of 10% for two of the cases. The 
average heart volume receiving dose above or equal to V15 (+ 1σ) on the conventional 
plan was 9.5 +6.2 % and 9.5 + 4.6 % on the TomoTherapy plan. There were no 
significant differences in the volume receiving > 15 Gy was observed between the 
conventional and the TomoTherapy plans (p = 0.98).  
Table 20. Percent volume of the heart receiving > 15 Gy  
Patient  Conventional TomoTherapy 
1 4.3 4.5 
2 4.6 6.8 
3 12.0 12.1 
4 17.1 14.5 
5 4.1 1.9 
 
Table 21 shows the calculated NTCP values for the heart. There were no significant 
differences in the NTCP for excess cardiac mortality after radiotherapy between the 
conventional and the TomoTherapy plans (p = 0.31). The average of the NTCP (+ 1σ) on 




Table 21. Calculated NTCP values for excess cardiac mortality due to Ischaemic disease 
after radiotherapy 
Patient Conventional TomoTherapy 
1 0.0009 0.0002 
2 0.0018 0.0003 
3 0.004 0.004 
4 0.02 0.007 
5 0.0005 0.0002 
 
3.7.4. Contralateral Breast 
Table 22 lists the average dose to the contralateral breast. The overall average of the 
mean dose of the contralateral breast on the conventional plan was 0.4 and 2.95 on the 
TomoTherapy plan.  
Table 22. Dmean (Gy) for contralateral breast (Average + Standard deviation) 
Patient Age (yrs) Conventional TomoTherapy 
1 73 0.1 + 0.1 3.20 + 1.58 
2 53 0.1 + 0.1 2.07 + 1.37 
3 49 0.1 + 0.1 2.10 + 0.76 
4 39 0.7 + 0.5 3.77 + 2.75 
5 49 0.8 + 0.8 3.60 + 1.93 
 
Table 23 lists the V5contralateral breast. There were differences in the contralateral 
breast volume receiving > 5 Gy between the conventional and the TomoTherapy plans (p 
= 0.08). The average of the V5contralateral breast (+ 1σ) on the conventional plan was 
0.0 % and 12.7 + 11.9 % on the TomoTherapy plan. 
Table 23. Percent volume of the contralateral breast receiving > 5 Gy  
Patient Conventional TomoTherapy 
1 0 13.1 
2 0 3.0 
3 0 0.9 
4 0 30.6 
5 0 15.9 
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Age dependence effect of radiation induced breast cancer was ignored when 
calculating the SCCP values (Table 24) for the contralateral breast. There was 
statistically significant difference in the SCCP after radiotherapy between the 
conventional and the TomoTherapy plans (p = 0.0001). The average of the SCCP (+ 1σ) 
was 0.002 + 0.002 for the conventional plan and 0.016 + 0.003 for the TomoTherapy 
plan.  
Table 24. Calculated SCCP for the contralateral breast after radiotherapy  
Patient Conventional TomoTherapy 
1 0.0001 0.0178 
2 0.0003 0.0125 
3 0.0004 0.0131 
4 0.0046 0.0183 
5 0.0047 0.0191 
 
3.7.5. Normal Tissue 
Table 25 lists the percent volume of normal tissue receiving 5 to 25 Gy. There was a 
statistically significant difference between the rival plans in the percentage of normal 
tissue volume that received 5 to 25 Gy (p = 0.002). The overall average of on the 
conventional plan (+ 1σ) was 23.4 +15.5 cm3 and 84.6+ 26.7 cm3 on the TomoTherapy 
plan. 
Table 25. Volume of normal tissue (delineated tissue volume except critical structures) 
receiving between 5 and 25 Gy 
Patient Conventional TomoTherapy 
1 17.6 111.7 
2 11.6 61.9 
3 9.2 52.4 
4 32.7 89.1 
5 45.7 108.0 
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Table 26 lists the SCCP values for normal tissue. There was a statistically significant 
difference in the SCCP values between the rival plans (p = 0.001). The average of the 
SCCP on the conventional plan (+ 1σ) was 0.003 + 0.002 and 0.010 + 0.003 on the 
TomoTherapy plan.  
Table 26. Calculated SCCP values for normal tissue 
Patient Conventional TomoTherapy 
1 0.003 0.012 
2 0.002 0.008 
3 0.002 0.007 
4 0.004 0.009 
5 0.006 0.014 






The focus of this study was to show TomoTherapy could deliver dose distributions a 
radiation oncologist judges to be equal to or better than that of a conventional electron 
plan. Physical dose-volume and radiobiological metrics were calculated and used to 
evaluate the treatment plans in addition to the radiation oncologist’s critique. 
4.1. Similarities Between The TomoTherapy and Conventional Plans 
Overall, the TomoTherapy plan was very similar to the conventional electron beam 
plan in treating the CW PTV while sparing critical structures adjacent to the CW PTV. 
There was no statistically significant difference in the CW TCP values between the 
TomoTherapy and conventional plans, although there was considerable difference in 
PTV dose homogeneity. The values for V20lung and NTCP for the ipsilateral lung were 
similar (i.e., no significant difference) between the two treatment plans, as was the values 
for V15heart, V30heart, and NTCP for the heart. From this study, one can assume with some 
degree of confidence that TomoTherapy is able to plan a PMRT that is as good as the 
conventional electron beam PMRT plan so far as TCP and NTCP are concerned. 
4.2. Differences Between The TomoTherapy and Conventional Plans 
As expected, the Tomotherapy plan showed better PTV dose uniformity compared to 
the conventional plan (Table 12).  Dose uniformity was insured by giving a high 
importance to the PTVs (CW and SCl/AX), and as a result, the TomoTherapy plan 
produced a significantly more uniform dose distribution in the PTV. Also, the 
conventional plan had at least a 10% dose gradient because of the method of generating 
the PTVs (i.e., the 90% isodose line was utilized to generate the PTV). Hot spots in the 
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field junctions added to the PTV dose inhomogeneity in the conventional plan. A 
difference in PTV dose homogeneity, mostly due to the abutting of the electron fields, 
were slightly over stated as the effect of edge feather were not included in the calculation. 
On the other hand, the conventional plan successfully avoided irradiating the 
contralateral breast. In all five cases, the volume receiving 5 Gy or more was negligible 
(Table 23). In order to stop dose exposure to the contralateral breast, a higher importance 
factor was assigned compared to other critical structures during the optimization of the 
TomoTherapy plan. This helped reduce the dose to the contralateral breast; however, the 
nature of beam arrangements and modality made dose reduction difficult for the 
TomoTherapy. As a result, the average dose to the contralateral breast was higher 
compared to the conventional plan. The average for all five patients was increased from 
0.4 Gy on the conventional plan to 2.95 Gy on the TomoTherapy plan. No excess breast 
cancer risk has been found among woman irradiated at age 40 years or older (Leeuwen et 
al. 2005). Boice et al, (1992) showed radiation exposure after the age of 45 years entails 
little, if any risk (relative risk, 1.01) of radiation-induced breast cancer for population of 
an average age of 51.7 years woman exposed with mean radiation dose to the 
contralateral breast be 2.82 Gy (maximum 7.10). Storm et al, (1992) also showed little if 
any risk (relative risk, 1.04) of radiation-induced breast cancer for population of an 
average age of 51 years woman exposed with mean radiation dose to contralateral breast 
estimated to be 2.51 Gy. Relative risk is ratio of the probability of the event occurring in 
the exposed group vs. the control (non-exposed) group. In the current study, the average 
age for the five patients was 53 years and the overall average mean dose was 2.95 Gy. 
Given the conclusions of the studies mentioned above, the risk of developing radiation 
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induced breast cancer is comparable with other PMRT techniques for the five patients 
studied using the TomoTherapy.  
Two assumptions were made when calculating SCCP for the contralateral breast. (1) 
Age dependence effect of radiation induced breast cancer was ignored and (2) incidence 
of solid tumor induction in the contralateral breast was only calculated. The SCCP 
modeling for the TomoTherapy plan indicates a higher prediction of SCCP for the 
TomoTherapy plan relative to the conventional plan (Table 24). This may be attributed to 
the increased mean dose observed on the TomoTherapy plan (Table 22). The study 
recommends that further studies that attempt to reduce dose to the contralateral breast 
should be done before implementing TomoTherapy clinically as PMRT technique for 
young patients less than 30 yrs of age who experience long survival times and may be at 
risk of radiation-induced cancer. Hancock et al. (1993) showed that for women treated for 
Hodgkin’s disease with therapeutic radiation before 30 years of age are at markedly 
increased risk for breast cancer.  
According to Schneider et al. (2005a), solid tumor induction anywhere in the body 
tends to peak in the dose range of 5 to 25 Gy. Hence the present study noted the volume 
receiving between 5 and 25 Gy and found larger normal tissue volumes on the 
TomoTherapy plan compared to the conventional plan. This might be the reason why the 
SCCP for normal tissue was higher on the TomoTherapy plan compared to the 
conventional plan, but on the average, the calculated SCCP values for both rival plans 
were found to be very small. Limiting high dose to critical structures (ipsilateral lung and 
heart) proximal to the PTVs (CW and SCl/AX) the ipsilateral lung and heart and the 
nature of TomoTherapy’s beam arrangements and modality resulted in low dose spread to 
normal tissue. Dose limiting structures were used to minimize dose to the normal tissue 
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but could not eliminate the dose without negatively impacting the treatment plan. As a 
result of the low dose spread to a large area of the normal tissue, TomoTherapy showed 
relatively higher risk of SCCP. The overall SCCP value when using TomoTherapy plan 
for the five studied patients was 0.088 + 0.012 (total lung = 0.062, contralateral breast = 
0.016, and normal tissue = 0.010) compared to the conventional plan 0.037 + 0.011 (total 
lung = 0.032, contralateral breast = 0.002, and normal tissue = 0.003). The influence of 
chemotherapy and possible genetic susceptibility are not included in the radio-biological 
models (TCP, NTCP and SCCP). Also, there is lack of accuracy in dos reconstruction in 
patient treated decade ago. Hence, the absolute values generated by radiobiological 
models thus far are not accurate and as a result should not be used to predict response. 
However, the models are sufficient to compare rival plans. 
4.3. Overview of Doctor’s Review 
After reviewing the spatial dose distributions and the superimposed DVHs of both the 
conventional and the TomoTherapy plans, the radiation oncologist ranked the 
TomoTherapy plan to be superior in all cases (marginally superior in one case). The basis 
for his judgment was his clinical experience. Absence of hot and cold spots to the PTV 
for the TomoTherapy plan was the reason why he chose the TomoTherapy plan over the 
conventional plan. He liked (1) the significant improvement in dose uniformity seen in 
the PTV on the TomoTherapy plan, (2) the ability of the TomoTherapy to avoid 
complexities that arise from matching abutting fields, (3) the absence of necessity for the 
use of more than one modality (electrons/photons), and (4) the ability of the 
TomoTherapy to spare specified organs at risk (e.g. ipsilateral lung). Also seen as a 
bonus feature was the on board megavoltage computed tomography (CT), which verifies 
setup in three dimensions rather than in two. On the other hand, he had a concern in the 
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accuracy of TomoTherapy dose delivery to the skin surface due to the effect of breathing 
motion. The chest wall is the site at greater risk of recurrence in patient undergoing 
mastectomy (Recht et al. 1996). For patient with locally advanced disease (stage IIIB), 
achieving a high skin and subcutaneous dose may be more important (Thomas et al. 
1989). It is also the clinical experience of radiation oncologists at MBPCC that most 
recurrences (failure to control locoregional tumor) occur on the skin. 
Both rival plans showed similarity on what the radiation oncologist set as a 
requirement for the total lung and the heart (Table 16 and Table 20 respectively). 
However, due to the nature of beam arrangements of the TomoTherapy delivery, only 
two of the five TomoTherapy plans met his contralateral breast requirement (maximum 






The study showed that TomoTherapy can deliver dose distributions the radiation 
oncologist judges to be equal to or better than that of a conventional electron beam 
PMRT plan for five CW treatment plans. TomoTherapy showed improved dose 
homogeneity in the CW PTV with reduced dose to proximal critical structures (ipsilateral 
lung and heart). However, large volume of critical structures and normal tissue received 
low doses with TomoTherapy. As a result, SCCP for a contralateral breast and normal 
tissue were found to be higher with the TomoTherapy plan when compared to the 
conventional plan. This may be a concern for young patients (< 30 yrs) who experience 
long survival times and as a result may be at risk of radiation-induced cancer; however, 
this was not considered a significant factor by the radiation oncologist reviewing the 
plans. 
In conclusion, the ability of the TomoTherapy to avoid complexities that arise from 
matching abutting fields and to spare specified normal tissue (e.g. ipsilateral lung) while 
maintaining a uniform dose distribution to the PTV  makes it an attractive candidate for 
PMRT. However, more studies should be done to address issues such as skin dose and 
the effect of breathing motion on the dose distribution before gaining complete 






6.1. Additional Treatment Studies 
Additional studies should be conducted to better compare conventional and 
TomoTherapy PMRT plans. These studies should include junction shift over the course 
of treatment should be modeled by the treatment planning system to reduce the hot spot 
seen in the dose distributions and DVHs.  Also, surgically-removed tumor beds are 
typically boosted to 60 Gy in 2Gy/fraction treatments after the CW is treated to 50 Gy. 
Whether the boosted portion of the CW can be treated at the same time as the rest of the 
CW, or if an additional TomoTherapy plan has to generated, is yet to be studied. 
6.2. Accuracy of Dose Calculation on Surface 
The accuracy of the TomoTherapy dose calculate on the skin surface is of interest. 
The dosimetric uncertainty in the surface and buildup region in IMRT cases has been 
documented by Chung et al. (2005) for the Pinnacle treatment planning system and by 
Mutic et al. (1999) for the Peacock treatment planning system (NOMOS Corp., 
Sewickley, PA). Hence, a careful experimental measurements and comparison to the 
TomoTherapy treatment planning system’s dose calculation in this superficial site are 
necessary as most breast cancer recur on the skin surface.  
6.3. Impact of Breathing Motion 
The effect of motion due to breathing may have significant impact on the study. 
Breathing motion is not so much an issue with conventional electron beam PMRT as the 
beams are perpendicular to the breathing motion. However, the TomoTherapy plan 
required greater weighting to beamlets incident on the CW at highly oblique, grazing 
angles to avoid excessive dose to the heart and lungs. Breathing motions would take the 
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CW out of the PTV area for a fraction of the treatment, and therefore a margin would 
have to be added to the CW PTV to account for breathing. Unfortunately expanding the 
PTV into the air above the CW would have a negative impact on the optimization of 
beamlet fluence patterns near the skin unless the patient is scanned with bolus allowing 
expansion of the ROI above the skin. 
6.4. Utility of Skin Collimation 
Typically when the CW is treated with photon beams, bolus is applied to the skin of 
the CW to insure adequate skin dose. Such a procedure would be performed for PMRT 
on the TomoTherapy. However, this study utilized patient CT scan data absent of bolus 
material and TomoTherapy does not provide an option for adding bolus material to the 
plan unless the patient is scanned with bolus. Skin dose is of great concern in PMRT as 
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Appendix A 
Radiation Oncologist Evaluation of Treatment Plans 
 
Date   :  
Patient:  
 
a. Evaluate the clinical acceptability of plans (scale 1-5) 
  
• How do you evaluate the TomoTherapy plan? Please circle 
one value that closely describes your observation. 
 
 1 2 3 4 5  
 
Acceptable  1 
Marginally acceptable 2 
Indifferent 3 
Marginally unacceptable 4 
Unacceptable 5 
 
• How do you evaluate the Conventional plan? Please circle 
one value that closely describes your observation. 
 
 1 2 3 4 5  
 
Acceptable  1 
Marginally acceptable 2 
Indifferent 3 




b. Compare the TomoTherapy plan with the conventional plan (either 
electron beam alone treatment or mixed beam treatment). 
i. Please circle one value that closely describes your observation, 
after comparing the TomoTherapy plan with the conventional pan.   
 
             1 2 3 4 5  
 
Superior  1 
Marginally superior 2 
Indifferent 3 






ii. Why do you prefer it? Is it, 
a. Better PTV coverage 
b. Less dose to the critical structure 
c. Less whole body dose 
d. other 
                 





ABR     American Board of Radiology  
AX    axillary  
CW    chest wall 
CT    computed tomography  
DVH    dose volume histogram  
dDVHs   differential dose-volume histograms  
FOV     field of view 
IHD     ischaemic heart disease 
ICRP   International Commission on Radiological Protection 
IGRT    image-guided radiotherapy  
IMRT    intensity-modulated radiotherapy 
IMN     internal mammary chain  
MVCT   mega-voltage computerized tomography system  
MBPCC    Mary Bird Perkins Cancer Center  
NTCP    normal tissue complication probability 
OAR    organ at risk 
PMRT   post-mastectomy radiation therapy  
PTV    planning PTV volume 
PWTF   partially wide tangent fields 
RAR    region at risk 
RHS    reverse hockey stick  
ROI   region of interest 
SCCP    secondary cancer complication probability  
SCl    supraclavicular  
SEER   Surveillance Epidemiology and End Results 
SCl/AX   supraclavicular/axillary nodes 
TCP   tumor control probability  
TERMA  total Energy Released per unit Mass 
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